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1. Introduction 
In this report, results are summarised from the eleventh proficiency test trial conducted by the 
National Food Institute (DTU Food) as the EU Reference Laboratory for Antimicrobial 
Resistance (EURL-AR). This proficiency test focuses on Salmonella and Campylobacter and is 
the sixth External Quality Assurance System (EQAS) conducted for these microorganisms (the 
first was EQAS 2006). In addition, the proficiency test for the third time includes an optional 
element consisting of genotypic characterization by PCR/sequencing of antimicrobial 
resistance genes of a selected Staphylococcus aureus and Salmonella spp. isolate. 
The objective of the EQAS is to monitor the quality of the antimicrobial susceptibility data 
produced by the NRL-AR and to identify areas or laboratories, for which guidance or 
assistance would be required as means of producing reliable susceptibility data. The goal until 
the 2008 iteration was to have all laboratories performing antimicrobial susceptibility testing 
(AST) with less than 7% incorrect interpretations. This was reconsidered at the EURL-AR 
workshop 2009, and as of the 2009 iterations, the goal is to have each laboratory performing 
AST with less than 5% incorrect interpretations (interpretations deviating from the expected 
results). For the optional genotypic characterisation, no specific acceptance level has been set. 
The data in this report are presented with laboratory codes. A laboratory code is known to the 
individual laboratory, whereas the entire list of laboratories and their codes is confidential and 
known only to the EURL-AR and the EU Commission. All conclusions are public.  
The technical advisory group for the EURL-AR EQAS scheme consists of competent 
representatives from all National Reference Laboratories for Antimicrobial Resistance (NRLs), 
who meet annually at the EURL-AR workshop.  
The AST data reported to EFSA by the Member States (MS) is based on the interpretation of 
the AST results. The basis for this EQAS evaluation is the interpretation of the AST result; as is 
also stated in the protocol, the “main objective of this EQAS is to assess and improve the 
comparability of surveillance and antimicrobial susceptibility data reported to EFSA by the 
different NRLs”. In addition, the participants of an EQAS should evaluate their own results and 
introduce corrective actions if necessary. The categorization of an uploaded interpretation as 
incorrect in the EURL-AR EQAS should induce the participant to perform a self-evaluation. 
This self-evaluation could very well include a comment on the fact that an acceptable deviation 
for MIC‐determination is ± one dilution step, which in some cases may affect the interpretation 
of the result. Therefore, the self-evaluation may lead to arguments which can defend the 
obtained results internally, yet, incorrect interpretations based on a one step dilution difference 
is still regarded as a deviation for the overall EQAS reporting, evaluation and in the database. 
The EURL-AR is accredited by DANAK (accreditation no. 516) as provider of proficiency test 
for zoonotic pathogens and indicator organisms in bacterial isolates (serotyping, identification, 
and antimicrobial susceptibility testing). 
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2. Materials and methods 
2.1 Participants 
A pre-notification (App. 1) of the EURL-AR EQAS on AST of Salmonella and Campylobacter 
was distributed on the 7th
Appendix 2 shows that 32 of the 38 participating NRLs were appointed by the individual 
Member States. Three NRLs were enrolled on equal terms as the designated NRLs, based on 
their participation in an EU funded concerned action (FAIR5-QLK2-2002-01146), the ARBAO 
II project (Antibiotic Resistance in Bacteria of Animal Origin). The laboratories in Croatia, 
Norway, Serbia and Switzerland were charged a fee for their participation in the EQAS, 
whereas the NRLs from EU Member States participated free of charge. 
 July 2011 by e-mail to the 40 NRLs in the EURL-AR-network 
(including Croatia, Iceland, Norway, Serbia and Switzerland). In addition, to the AST of 
Salmonella and Campylobacter, an optional genotypic characterization by PCR/sequencing of 
antimicrobial resistance genes of a selected S. aureus and Salmonella spp. isolate was offered. 
The pre-notification was sent to NRLs in all EU countries except Luxemburg, where no NRL 
has been designated. One laboratory was not participating as they had neither Salmonella nor 
Campylobacter as their field of responsibility. In addition, Iceland did not participate in this 
iteration. 
Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella or 
both Salmonella and Campylobacter.  
The results from the NRLs designated by the MS are presented and evaluated in this report in 
addition to national reference laboratory in affiliated non-MS; i.e. results from 30 countries 
consisting of 34 sets of Salmonella results and 26 sets of Campylobacter results (i.e. results 
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from the three laboratories not designated by the MS but enrolled on equal terms as these are 
not further presented or evaluated in this report). Figure 1 illustrates that out of the participating 
countries, five, for various reasons, uploaded Salmonella results only for evaluation (Bulgaria, 
Croatia, Greece, Italy and Serbia), whereas 26 tested both Salmonella and Campylobacter. Six 
laboratories participated in the optional genotypic characterisation of the S. aureus and/or the 
Salmonella spp. isolate (not illustrated in Figure 1).  
2.2 Strains 
Eight Salmonella strains and eight Campylobacter strains were selected for this trial among 
isolates from the strain collection at DTU Food. Individual sets of the Salmonella strains were 
provided as agar stab cultures and the Campylobacter strains as charcoal swabs. 
The shipment of strains also included the lyophilised international reference strains for 
antimicrobial susceptibility testing; Escherichia coli CCM 3954 (ATCC 25922) and 
Campylobacter jejuni CCM 6214 (ATCC 33560) purchased at Czech Collection of Micro-
organisms (CCM), the Czech Republic. This was relevant only for the NRLs which had not 
been provided with these reference strains in previous EQAS’s conducted by DTU Food. 
Prior to distribution of the strains, AST was performed on the Salmonella and Campylobacter 
strains at DTU Food and verified by the US Food and Drug Administration (FDA). The 
obtained MIC values served as reference for the test strains (App. 3a and 3b). However, results 
from the following antimicrobials were not verified by FDA: cefotaxime, 
cefotaxime/clavulanic acid, ceftazidime, ceftazidime/clavulanic acid, imipenem, 
imipenem/EDTA, and trimethoprim for Salmonella and furthermore, chloramphenicol and 
streptomycin for Campylobacter. 
The test strains included for optional genotypic characterisation were an S. aureus and (EURL 
GEN 3.1) exhibiting resistance to cefoxitin, penicillin, streptomycin, tetracycline, and tiamulin, 
and a Salmonella spp. (EURL GEN 3.2) exhibiting resistance to amoxicillin-clavulanic acid, 
ampicillin, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cephalothin, 
cefpodoxime, ceftiofur, chloramphenicol, florphenicol, gentamicin, spectinomycin, 
streptomycin, sulfamethoxazole, and tetracycline (selection of antimicrobials was different 
from those used for the AST in this EQAS). 
2.3 Antimicrobials 
The antimicrobials used in the EQAS are listed in the protocol (App. 4b) and were included 
mainly according to the recommendations of the European Food Safety Authority (EFSA) 
monitoring programme [Report of the Task Force of Zoonoses Data Collection including a 
proposal for a harmonized monitoring scheme of antimicrobial resistance in Salmonella in fowl 
(Gallus gallus), turkeys, and pigs and Campylobacter jejuni and C. coli in broilers, the EFSA 
Journal (2007), 96,1-46]. A few additional antimicrobials have been added as indicated in the 
protocol due to included element on detection of ESBL production. 
The selection of antimicrobials used in the trial for Salmonella was: ampicillin, cefotaxime, 
cefotaxime/clavulanic acid, ceftazidime, ceftazidime/clavulanic acid, ceftiofur, 
chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfonamides 
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(sulfamethoxazole), tetracycline and trimethoprim. Additionally, cefoxitin was used for 
detection of ampC, and imipenem, imipenem/EDTA for detection of metallo-beta-lactamases. 
Minimum Inhibitory Concentration (MIC) determination of the Salmonella test strains was 
performed using the Sensititre system from Trek Diagnostic Systems Ltd, UK. For ESBL 
confirmatory test, the analysis included MIC determination by microbroth dilution (panel code 
ESB1F), and in addition, for the antimicrobials cefotaxime/clavulanic acid, cefoxitin, 
ceftazidime/clavulanic acid, tests were performed using E-test from AB-Biodisk, Sweden. The 
method guidelines used were according to the Clinical and Laboratory Standards Institute 
(CLSI) document M7-A8 (2009),
For Campylobacter the following antimicrobials were included: chloramphenicol, 
ciprofloxacin, erythromycin, gentamicin, nalidixic acid, streptomycin, and tetracycline. MIC 
determination was performed using the Sensititre systems from Trek Diagnostic Systems Ltd, 
UK, according to guidelines from the CLSI document M45-A2 (2010) “Methods for 
Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious 
Bacteria” (Approved Guideline – Second Edition) and M31-A3 (2008) “Performance Standards 
for Antimicrobial Disk and Dilution Susceptibility Tests for Bacterial Isolated From Animals” 
(Approved Standard – Third Edition). 
 “Methods for Dilution Antimicrobial Susceptibility Tests for 
Bacteria That Grow Aerobically” (Approved Standard - Eigth Edition), document M100-S21 
(2011) “Performance Standards for Antimicrobial Susceptibility Testing” (Twenty-First 
Informational Supplement) and document M31-A3 (2008) “Performance Standards for 
Antimicrobial Disk and Dilution Susceptibility Tests for Bacterial Isolated From Animals” 
(Approved Standard – Third Edition). 
2.4 Distribution 
On October 24th
International Air Transport Association
, 2011, the cultures and a welcome letter (App. 4a) were dispatched in double 
pack containers (class UN 6.2) to the participating laboratories as UN3373, biological 
substance category B, according to the  (IATA) 
regulations.  
2.5 Procedure 
Through the EURL-AR website, http://www.eurl-ar.eu/, the laboratories were provided with 
protocols and information regarding the handling of the test strains and reference strains (App. 
4b, c, d, e). The participants were instructed to subculture the strains according to the 
description in the protocol prior to performing the AST. Furthermore, participant receiving a 
ATCC reference strain were requested to save and maintain this for future proficiency tests. 
The aim is that only MIC methods are used when performing AST for monitoring conducted by 
the Commission, and thereby also when performing the EURL-AR EQAS’s. Consequently, it 
was decided in May 2007 by the participants at the EURL-AR workshop that the NRLs should 
work towards harmonising to MIC methods for these AST analyses. Additionally, it was agreed 
that all NRLs should work towards covering the antimicrobial panel and epidemiological cut-
off values recommended by the EURL-AR. For this EQAS, the participants were instructed to 
use as many as possible of the antimicrobials listed, using the method carried out when 
performing monitoring for EFSA. 
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The cut-off values recommended by EFSA should be used (listed in the protocol). All cut-off 
values used in the interpretation of the Campylobacter MIC results have been developed by 
EUCAST (www.eucast.org). This is also the case for Salmonella with the exception of 
sulphonamides, where the value from CLSI was used according to the description in the 
protocol (App. 4b).  
Participants using disk diffusion (DD) and E-test were recommended to interpret their results 
according to their individual routine, categorising the test strains into the terms resistant and 
susceptible. A categorisation as ‘intermediate’ was not accepted. The breakpoints used were 
submitted to the web based database. Breakpoints for disk diffusion for Salmonella are listed in 
Appendix 5.  
It should be noted that for AST of Campylobacter only MIC methods are recommendable, i.e. 
broth or agar dilution methods. The EURL-AR does not recommend the use of either disk 
diffusion or E-test for AST of Campylobacter. In addition, when reporting monitoring data to 
EFSA these have to be submitted as MIC-results. It was agreed at the EURL-AR workshop 
2009 that only MIC results for Campylobacter ASTs are accepted.  
The laboratories were instructed to upload the obtained MIC values (mg/L) or inhibition zone 
diameters (mm) and the susceptibility categories (resistant or susceptible) to the database 
through a secured individual login. Alternatively, the record sheets from the protocol could be 
sent by fax to DTU Food. The website was open for data entry in the period from the 25th of 
October 2011 to the 22nd
Detection of ESBL-producing strains should be performed and interpreted according to 
recommendations by EUCAST described in the protocol. Concerning the cephalosporins used 
when detecting ESBL-producing strains in this EQAS, MIC values and interpretations for these 
antimicrobials should be reported as found.  
 of December 2011. 
Results from the reference strains should also be entered into the database. The results would 
consist of MIC values for the reference strains E. coli (ATCC 25922) and C. jejuni (ATCC 
33560) or, for E. coli (ATCC 25922), the inhibition zone diameters in millimetres. The results 
should be in agreement with the quality control ranges according to the relevant guidelines; i.e. 
the CLSI documents M31-A3 (2008) or M100-S21 (2011); The Sensititre System (Trek 
Diagnostic Systems Ltd, UK); or E-tests (AB-Biodisk, Sweden) (App. 7). 
For the optional PCR-testing of the selected Gram-positive and Gram-negative isolate, 
participating laboratories were requested to report the genes harboured in the test strain. The 
genes listed in the table in the protocol (App. 4b) were included in the test. Identification of 
additional genes not listed in the protocol was not evaluated by the database. The results were 
evaluated based on the actual genes identified. The variants of TEM-, CTX-, SHV-, CMY-, 
OXA-genes as well as the gyrA-mutations and parC-mutations were additionally evaluated. For 
gyrA and parC, the mutation site located at a specific codon was evaluated in the same way as 
the genes.  
The participating laboratories were encouraged to use their own laboratory’s method(s) for the 
PCR-testing. The expected results were obtained by miniaturized microarray; for the Gram-
positive strain Identibac S. aureus Genotyping test was performed by Alere Technologies 
GmbH, Germany, detecting 333 genetic markers including mecA and antimicrobial resistance 
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genes groups such as betalactamases, macrolides, lincosamides, streptogramins, 
aminoglycosides, tetracycline, chloramphenicol, vancomycin and others. The expected results 
for the Gram-negative strain were obtained at the EURL-AR by using Identibac Amr-ve array 
tubes; New Haw, Addlestone, Surrey, United Kingdom) containing probes for most relevant 
Gram-negative antimicrobial resistance gene groups such as quinolone, sulfonamide, 
tetracycline, aminoglycoside, carbenicillinase, chloramphenicol exporter/acetyltransferase, 
florfenicol, trimethoprim, plasmidic ampC, beta-lactam antimicrobials as well as class 1/2 
integrase. Analysis was performed as recommended by the manufacturer. PCR was conducted 
for confirmation of weak array results. The positive identifications of genes have not been 
verified elsewhere. 
Subsequent to the submission deadline, the laboratories were instructed to login to the secured 
database once again to retrieve the database generated, individual evaluation report. The 
evaluation reports assessed the submitted results, describing all deviations from the expected. 
Deviations in the interpretation as resistant or susceptible were categorised as ‘incorrect’, as 
was also deviations in confirmation of an isolate as ESBL-producer or ampC.  
The EURL-AR is aware that there are two different types of interpretative criteria of results, 
clinical breakpoints and epidemiological cut-off values. The terms ‘susceptible’, ‘intermediate’ 
and ‘resistant’ should be reserved for classifications made in relation to the therapeutic 
application of antimicrobial agents. When reporting data using epidemiological cut-off values, 
bacteria should be reported as ‘wild-type’ or ‘non-wild-type’ (Schwarz et al., 2010). Due to the 
different methods of AST used by the participants and also to simplify the interpretation of 
results, throughout this report, we will still maintain the terms susceptible and resistant, even in 
the cases where we are referring to wild-type and non-wild-type strains. 
The database included questions for evaluation of the EQAS as well as questions regarding the 
individual laboratories’ work in the area of AST. Few laboratories used these features for 
sending comments to the EURL, those who did have received direct reply when relevant. Test 
ranges for concentrations used when performing MIC for AST were collected in Appendix 8. 
 
3. Results 
The participants were asked to report results, including MIC values or inhibition zone 
diameters obtained by DD together with the categorisation as resistant or susceptible. Only the 
categorisation was evaluated, whereas the MIC values and disk diffusion inhibition zones were 
used as supplementary information. 
At the EURL-AR workshop 2008, the network agreed that if less than 75% of the results were 
correct, based on strain/antimicrobial combination, these results should be further analysed and 
possibly omitted from evaluation. In the present EQAS this occurred in two cases: for the 
combination of the test strains S-6.2/streptomycin and for S-6.6/streptomycin with a level of 
agreement with the expected results at 55% and 48%, respectively (Appendix 9a and 9b present 
the total number of correct/incorrect results for each strain/antimicrobial-combinations).  
In both cases with streptomycin, the expected MIC (32 mg/L, resistant) and the cut-off value 
(>16 mg/L) were within one fold dilution difference. The expected values were determined by 
two different institutions; DTU Food and FDA and were consistent with MIC results of 
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32mg/L or ≤32mg/L. For the test strain S-6.2 the presence of aadA2 was confirmed by PCR by 
the EURL-AR, whereas the genes strA and strB were not detected in either of the two test 
strains.  
Figure 2 illustrates the distribution of the different MIC values together with the interpretation 
of these values obtained by participants performing MIC for the combination of strain S-
6.2/streptomycin and S-6.6/streptomycin. The figure shows a distribution of MIC’s with the 
expected value at 32mg/L and the majority of participants obtaining AST results one MIC-
dilution below the expected result. Results from four participants performing disk diffusion 
have been excluded from these particular analyses. 
 
Figure 2: Distribution of the different MIC values obtained by participants performing MIC for the 
combination S-6.2/streptomycin and S-6.6/streptomycin. 
Based on the facts that the precision of the method relies on various factors, including the 
media content, the type of microbroth panels as well as a number of others, and the fact that an 
MIC result obtained by the microbroth method or agar dilution can vary +/- one dilution step 
from the obtained MIC, these two strain/antimicrobial combinations have been excluded from 
the evaluation.  
3.1 Methods used by EQAS-participants 
In the Salmonella trial, 28 laboratories used MIC determination, and six laboratories used disk 
diffusion. For the Campylobacter trial, all 26 included laboratories reported the use of MIC 
determination (microbroth or agar dilution), in addition, one laboratory submitted disk 
diffusion results for Campylobacter which have been disregarded in this report.  
3.2 Deviations by strain and antimicrobial 
The list of deviations is shown in Appendix 10a and 10b. Figure 3 shows the total percentage of 
deviations from the expected results of AST performed by participating laboratories. For the 
Salmonella strains, 98.1% of the AST’s were interpreted correctly. For the Campylobacter 
strains, 97.4% of AST’s were correctly tested. The internal control strains have mainly 
followed the trend in deviation level of the different EQAS trials (Figure 3). The deviation level 
in 2011 is acceptable for both the Salmonella and the Campylobacter trials.  
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Figure 3: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of 
deviations for antimicrobial susceptibility testing performed by participating laboratories 
 
Figure 4: The total percentage of deviations for AST’s performed using MIC-methods as opposed to 
disk diffusion.  
Figure 4 shows the total percentage of deviations from the expected results of AST performed 
by MIC-methods as opposed to disk diffusion. This is relevant for the Salmonella trial for 
which the deviation percentage is significantly higher (p<0.01) when AST is performed by disk 
diffusion compared to a MIC-method.   
The number of AST’s performed and the percentage of correct results for the individual 
Salmonella and Campylobacter strains in the EQAS, are listed in Table 1. Variations of 
obtained correct results ranged from 94.6-99.7% for Salmonella and from 96.3-100% for 
Campylobacter.  
Table 2 illustrates the percentage of correct AST per antimicrobial by bacterial species. When 
testing Salmonella, it appeared that the antimicrobial with the lowest percentage of correct AST 
was ciprofloxacin (94.3%) which could be attributed to the strains S-6.3 and S-6.7 which both 
exhibit reduced susceptibility towards this antimicrobial.  
0 
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EQAS 2011 – Salmonella EQAS 2011 – Campylobacter 
Test strain AST in total % correct Test strain AST in total % correct 
S-6.1 371 99.7   C-6.1 (C. jejuni) 169 97.6 
S-6.2 337 99.1   C-6.2 (C. jejuni) 163 96.3 
S-6.3 371 96.5   C-6.3 (C. jejuni) 170 96.5 
S-6.4 369 96.5   C-6.4 (C. jejuni) 169 98.2 
S-6.5 371 99.7   C-6.5 (C. coli) 176 97.2 
S-6.6 335 99.4   C-6.6 (C. coli) 176 96.6 
S-6.7 369 94.6   C-6.7 (C. coli) 176 97.7 
S-6.8 370 99.7   C-6.8 (C. coli) 176 100.0 
Table 1: The number of AST performed and the percentage of correct results for each strain of 
Salmonella and Campylobacter.  
Sulfamethoxazole also exhibits a low level of correct results, which to a large extent can be 
attributed to S-6.7 with an expected MIC at 64 mg/L (susceptible), and with a cut-off value at 
256 mg/L. The incorrect interpretations as resistant are caused by a three steps (or more) 
difference from the reference value which is likely to be caused by the fact that this 
antimicrobial in contrast to other antimicrobial has a bacteriostatic effect and therefore the MIC 
or the zone diameter result should be read where 80% of the growth is inhibited.  
EQAS 2011 % correct 
Antimicrobial Salmonella Campylobacter 
Ampicillin, AMP 100.0 - 
Cefotaxime, CTX 98.9 - 
Ceftazidime, CAZ 97.8 - 
Ceftiofur, XNL 98.4 - 
Chloramphenicol, CHL 100.0 100.0 
Ciprofloxacin, CIP 94.3 99.0 
Erythromycin, ERY - 98.0 
Gentamicin, GEN 98.9 99.0 
Nalidixic acid, NAL 97.7 95.5 
Streptomycin, STR 97.0 93.1 
Sulphonamides, SMX 95.4 - 
Tetracycline, TET 99.3 98.5 
Trimethoprim, TMP 99.6 - 
Table 2: Percentage of correct antimicrobial susceptibility tests per antimicrobial by microorganism. 
In grey, antimicrobials recommended in the EFSA zoonosis monitoring manual.  
For Campylobacter, streptomycin had the lowest deviation level which was interestingly for all 
deviations caused by susceptible results identified as resistant. Two laboratories (#4 and #19) 
each had five of the 14 deviating results from this antimicrobial, with laboratory #4 in fact in 
four of the five cases obtaining a level of MIC incorrectly categorized as resistant. 
ESBL-producing Salmonella test strains 
It was decided on the EURL-AR workshop 2008 that the testing of ESBL production in 
Salmonella should be mandatory. The laboratories were asked to detect the ESBL-producing 
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Salmonella strains and to perform confirmatory testing on all relevant strains resistant to 
cefotaxime (CTX), ceftazidime (CAZ) or ceftiofur (XNL) according to the protocol (App. 4b).  
The four test strains; S-6.1, S-6.3, S-6.4 and S-6.8 were ESBL-producers, which was confirmed 
by the majority of the 34 laboratories participating in the Salmonella EQAS. As the ESBL 
detection part is mandatory in this EQAS, all results are evaluated below. 
Three of the ESBL-producing strains were so-called ‘true ESBLs, harbouring blaTEM-52 (S-6.1), 
blaCTX M-15 and blaSHV-12 (S-6.3) and blaCTX M-15-like (S-6.4), whereas one was and ampC-
producing strain harbouring blaCMY-2 
There is a difference in the number of cephalosporins used by the laboratories in their routine 
test for ESBL production; five compounds are included in this proficiency test: cefotaxime, 
ceftazidime, ceftiofur, cefotaxime/clavulanic acid and ceftazidime/clavulanic acid. The first 
three are used for initial screening whereas the last two are used for confirmatory test (the 
combination disk method).  
(S-6.8) (Table 3).  
 
Strain S-6.1 
(CTX M-52) 
Strain S-6.3 
(CTX M-15/ 
SHV-12) 
Strain S-6.4 
(CTX M-15 like) 
Strain S-6.8 
(CMY-2) 
Proportion of laboratories 
succesfully using different 
cephalosporins for 
screening 
(correct confirmation of 
ESBL production) 
CTX, CAZ, XNL 6/7 (86%) 6/7 (86%) 5/7 (71%) 5/7 (71%) 
CTX, CAZ 21/22 (95%) 21/22 (95%) 22/22 (100%) 21/22 (95%) 
CTX, XNL 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 
CTX 4/4 (100%) 4/4 (100%) 4/4 (100%) 3/4 (75%) 
Confirmed ESBL-producer 32/34 (94%) 32/34 (94%) 32/34 (94%) 2/34 (6%) 
FOX - R - - 29/34 (85%) 
ampC confirmed - - - 30/34 (88%) 
ampC not confirmed 34/34 (100%) 34/34 (100%) 34/34 (100%) 4/34 (12%) 
Table 3: Proportion of laboratories that obtained the expected result. Number and percentages of laboratories 
which correctly detected and confirmed the ESBL-producing Salmonella strains. Fields shaded in grey indicate an 
unexpected result. 
In ten occasions, the ESBL-producing strain was not detected. Four of these deviations were 
due to one laboratory which did not perform the confirmatory testing (laboratory #54). 
Additional three deviations were laboratories #21, #26 and #56 failing to detect the strains S-
6.1, S-6.2 and S-6.4, respectively, and the remaining cases were laboratories #38, #39 and #41 
failing to detect S-6.8 as an ampC-producer. In two occasions, the ampC-producer, S-6.8, was 
incorrectly confirmed as an ESBL-producer (laboratories #4 and #22). 
Eleven laboratories uploaded an MIC-ratio as a result, and 17 uploaded the increase of 
inhibition zone diameter, additionally, three laboratories uploaded both an MIC and an 
inhibition zone diameter result.  
According to the expected results, none of the laboratories reported resistance to 
cephalosporins for any of the non-ESBL-producing strains.  
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3.3 Deviations by laboratory 
Figure 5 and 7 illustrate the percentage of deviations for each participating laboratory. The 
laboratories are ranked according to their performance determined by the percentage of 
deviating results in tests with antimicrobials recommended by EFSA. These results will be the 
focus of the evaluation in the following sections. Obtained results including all antimicrobials 
mentioned in the protocol are additionally indicated. In Figure 6 and 8, the total amount of 
deviations in percentages is illustrated by number of laboratories.  
 
Figure 5: Individual participants’ deviations in percent of their total number of Salmonella AST’s. An 
asterisk indicates that the laboratory performed AST using disk diffusion 
3.3.1 Salmonella trial  
Twenty-nine of the laboratories obtained a result within the acceptance limit at 5% deviations 
for the Salmonella strains. The maximum percentage of deviations was 9.3%. 
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Figure 6: The number of laboratories listed in intervals of percent of total deviations. The 
green line marks the 5% acceptance limit set by the EURL-AR 
Figure 6 illustrates that the performance of five (17%) laboratories resulted in a deviation level 
above the level of performance expected by the EURL-AR (#4, #26, #38, #40, and #54), 
however, none of the laboratories are regarded as outliers. As illustrated in Figure 5, deviation 
levels including all antimicrobials mentioned in the protocol to some extent varies from the 
deviation levels regarding EFSA-antimicrobials, only.  
3.3.2 Campylobacter trial 
In the Campylobacter trial most laboratories performed very well. Applying the 5% acceptance 
threshold, 23 of 26 participating laboratories performed acceptably, with 20 laboratories having 
no deviations (Figure 7 and 8). Three laboratories present a deviation level above the 5% 
acceptance level (#4, #19, and #39) and are regarded as outliers.  
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Figure 7: Individual participants’ deviations in percent of their total number of Campylobacter AST’s.  
  
Figure 8: The number of laboratories listed in intervals of percent of total deviations.  
Deviation levels including results obtained for all antimicrobials mentioned in the protocol 
generally do not vary much from the deviation levels including results obtained for 
antimicrobials recommended by EFSA, only.  
3.4 Deviations by reference strains  
In the following section, deviations are defined as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality control (QC) acceptance intervals (App. 7). 
Values from the participants’ testing of the QC strains are listed in Appendix 6a and 6b, and in 
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Tables 4, 5 and 6 which summarize results from the laboratories’ quality control. For the 
Salmonella trial, all laboratories but one (#54) performed QC testing of the reference strain. For 
the Campylobacter trial, all 26 participating laboratories uploaded data from QC-testing on the 
reference strain. 
Table 4 presents the number of laboratories performing disk diffusion to test the E. coli 
reference strain (ATCC 25922). All obtained values were within the QC-range.  
EQAS 2011 Disk diffusion E. coli ATCC 25922 
  Proportion of 
labs outside 
QC range  
Obtained values in mm inhibition zones (min/max) 
Antimicrobial Below lower QC limit Above upper QC limit 
Ampicillin, AMP 0/4 (0%) - - 
Cefotaxime, CTX 0/5 (0%) - - 
Cefoxitin, FOX 0/4 (0%) - - 
Ceftazidime, CAZ 0/5 (0%) - - 
Ceftiofur, XNL  0/4 (0%) - - 
Chloramphenicol, CHL 0/5 (0%) - - 
Ciprofloxacin, CIP 0/4 (0%) - - 
Gentamicin, GEN 0/5 (0%) - - 
Imipenem, IMI 0/2 (0%) - - 
Nalidixic acid, NAL 0/5 (0%) - - 
Streptomycin, STR 0/5 (0%) - - 
Sulphonamides, SMX 0/3 (0%) - - 
Tetracycline, TET 0/5 (0%) - - 
Trimethoprim, TMP 0/4 (0%) - - 
Table 4: Obtained values for AST of E. coli ATCC 25922 by disk diffusion.  
The use of MIC determination for AST of the reference strain E. coli ATCC 25922 resulted in 
submission of data from 28 laboratories, five of which produced one value each outside the 
QC-limit as illustrated in Table 5.  
EQAS 2011 MIC determination E. coli ATCC 25922 
 Proportion of labs 
outside QC range  
Obtained values in MIC steps (min/max) 
Antimicrobial Below lower QC limit Above upper QC limit 
Ampicillin, AMP 0/28 (0%) - - 
Cefotaxime, CTX 0/28 (0%) - - 
Cefoxitin, FOX 0/6 (0%) - - 
Ceftazidime, CAZ 0/22 (0%) - - 
Ceftiofur, XNL  0/3 (0%) - - 
Chloramphenicol, CHL 0/28 (0%) - - 
Ciprofloxacin, CIP 4/28 (14%) - 1 step 
Gentamicin, GEN 0/28 (0%) - - 
Imipenem, IMI 0/3 (0%) - - 
Nalidixic acid, NAL 0/28 (0%) - - 
Streptomycin, STR 0/27 (0%) - - 
Sulphonamides, SMX 1/20 (5%) - 1 step 
Tetracycline, TET 0/28 (0%) - - 
Trimethoprim, TMP 0/28 (0%) - - 
Table 5: Obtained values for AST of E. coli ATCC 25922 by MIC determination 
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EQAS 2011 MIC determination C. jejuni ATCC 33560 
 Proportion of labs 
outside QC range  
Obtained values in MIC steps (min/max) 
Antimicrobial Below lower QC limit Above upper QC limit 
Chloramphenicol, CHL 0/19 (0%) - - 
Ciprofloxacin, CIP 0/25 (0%) - - 
Erythromycin, ERY 0/25 (8%) - - 
Gentamicin, GEN 3/24 (13%) 1 step 3 steps 
Nalidixic acid, NAL 1/25 (0%) 2 steps - 
Tetracycline, TET 2/25 (8%) - 1 step 
Table 6: Obtained values for AST of C. jejuni ATCC 33560 using MIC determination 
All 26 participating laboratories performed MIC determination for the C. jejuni reference strain 
ATCC 33560. Table 6 presents the proportion of the laboratories with results for the QC strain 
below or above the QC interval. Six deviations were seen, divided between five laboratories.  
3.5 Genotypic characterisation 
For the optional PCR-testing of selected isolates, four and six laboratories performed genotypic 
characterization on the Gram positive test strain GEN 3.1 and the Gram negative test strain 
GEN 3.2, respectively. In Appendix 11, information is collected on detected genes, genes 
which were tested but not detected, primers used, and references for the method used. For all 
the uploaded results, Table 7 shows very good correlation with the expected genes.  
Originally, GEN 3.2 was expected to harbour TEM-1b. This was not verified by any of the 
participating laboratories. Subsequent to the EURL-AR receiving the results, the GEN 3.2 was 
retested for TEM-1b, and the presence of the gene could not be verified. The expected results 
were adjusted and the relevant participating laboratories received direct information about the 
update. 
For the Gram positive bacteria, laboratory III used the MRSA array from Alere (ClonDiag) and 
PCR-primers described by Argudin et al, 2011 AEM. Laboratory IV also used this microarray 
and confirmed the results with PCR. 
For the Gram negative bacteria, laboratory I, IV and VIII used the Arraytube system from 
Identibac (AMR-ve genotyping) Alere Technologies GmbH for detection of most of the 
antimicrobial resistance genes. Laboratory I indicated that if the result for an antimicrobial was 
found through the Arraytube, no PCR-method was submitted (App. 11).  
In addition to the results mentioned in Appendix 11, for GEN 3.1, laboratory VII found the S. 
aureus test strain to be spa-type t011 (repeats 08-16-02-25-34-24-25). For GEN 3.2, laboratory 
III commented that no mutations conferring quinolone resistance were detected whereas 
laboratory VIII detected integrase int1.   
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  Lab I Lab III Lab IV Lab VI Lab VII Lab VIII 
EU
R
L 
G
EN
 3
.1
 Aminoglycosides aadE or aad(6)* NT NT NT  NT  
Betalactamases blaI NT 1 1  NT  
Betalactamases blaR NT 1 1  NT  
Betalactamases blaZ 1 IH 1 1  NT  
Betalactamases mecA 1 IH 1 1  1  
Streptogramins vga(A) 1 IH 1 NT  NT  
Tetracycline tet(K) 1 IH 1 NT  NT  
Tetracycline tet(M) 1 IH 1 1  NT  
 
EU
R
L 
G
EN
 3
.2
 Betalactams CMY-2 1/1 IH 1/1 P 1/1 NT NT 1/1 
Chloramphenicol floR 1 1 P 1 NT NT 1 
Streptomycin strA NT 1 P 1 NT NT 1 
Streptomycin strB 1 1 P 1 NT NT 1 
Streptomycin aadA 1 1 P 1 NT NT 1 
Sulfamethoxazole sul1 1 IH 1 P 1 NT NT 1 
Sulfamethoxazole sul2 1 1 P 1 NT NT 1 
Tetracycline tetA 1 1 P 1 NT NT 1 
Additional info       AmpC Cit  
Table 7: Results from genotypic characterisation.  
Legend: 
* aadE and aad(6) are synonyms for the same aminoglycoside resistance gene  
1  indicates identification in accordance with the expected  
-  indicates identification not in accordance with the expected 
1/1  indicates ‘correctly identified gene or gene group’/’specific gene or mutation correctly identified’ 
1/-  indicates that the PCR-product was not sequenced to obtain a specific gene- or codon mutation 
NT  indicates ‘Not tested’ 
P indicates that a published PCR-method was used  
IH  indicates that an in-house protocol was used 
Shaded fields indicate that no results were uploaded for the test strain. 
Laboratory numbers are not consistent with the numbers otherwise used in this report, but they are 
consistent with the number used for the genotypic characterisation in former EQAS iterations. 
 
4. Discussion 
4.1 Salmonella trial  
Overall, the percentage of correct antimicrobial susceptibility test results of Salmonella was 
98.1%. The majority (n=29) of participants obtained satisfactory results according to the level 
of acceptance (<5% deviation). A significant difference (p<0.01) was obtained when 
comparing results obtained by the use of disk diffusion and a MIC method. 
As indicated in Figure 3, the overall quality of the results in the 2011-EQAS would appear to 
be at the same level compared to the performance in the former four iterations.  
Salmonella test strain S-6.7 was susceptible to sulphonamides with an MIC at 64µg/mL but 
appeared to render a number of incorrect interpretations as resistant (8/32). The reason for this 
is likely to be that this drug is bacteriostatic and not bacteriocidal, why the reading of the MIC 
or the inhibition zone should be where 80% of the full growth is inhibited. Interestingly, other 
strains had the same expected MIC with no indication of the same problem. 
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Ciprofloxacin appeared to cause problems for two of the strains (S-6.3 and S-6.7) which each 
harbour a plasmid mediated resistance gene; qnrB and qnrD, respectively, and thus exhibit low-
level ciprofloxacin resistance and nalidixic acid susceptibility. The participants generally found 
these isolates sensitive to nalidixic acid (88% and 94%), whereas a lower number found the 
strains resistant to ciprofloxacin (82% and 82%). In total for both of the test strains in 
questions, twelve deviating results have been submitted for ciprofloxacin. Of these, ten were 
submitted by laboratories performing disk diffusion for AST. These laboratories (#18, #38, 
#40, #54 and #56) could benefit from referring to the recommendations published by Cavaco 
and Aarestrup (2009). All four ciprofloxacin-resistant Salmonella test strains exhibit reduced 
susceptibility to this antimicrobial why the use of a 1µg ciprofloxacin disk is recommended 
when performing DD. Applying the interpretative criteria recommended by Cavaco and 
Aarestrup to the results obtained by laboratory #54, produce a categorisation as resistant for all 
the strains in question. 
Three (#38, #40, and #54) of the five laboratories exhibiting a deviation level higher than 5% 
performed disk diffusion for AST and obtained deviation levels at 5.1%, 7.7%, and 9.3% , 
respectively. The additional two laboratories (#4 and #26) performed MIC for AST and 
obtained deviation levels at 5.1% and 6.4%, respectively. None of these were defined as 
outliers. 
For laboratory #4, five of the six deviations on Salmonella test strains would have been 
eliminated if the interpretation of the MIC’s had followed the cut-off values presented in the 
protocol. This would have rendered a percentage of correct results at 98.8% for this laboratory.  
Laboratories #38, #40, and #54 are recommended to follow the recommendations published by 
Cavaco and Aarestrup (2009) and in addition, laboratory #54 is recommended to test the E. coli 
QC reference strain and also to submit these values for assessment in future EURL EQAS. 
Laboratory #26 obtained 4 deviations on the one test strain (S-6.3) which after investigating 
this in the laboratory could be attributed to a technical error causing test strain S-6.2 to be 
tested twice; once as S-6.2 and once as S-6.3 and thereby also ruling out the possibility of 
detecting the ESBL-production of the S-6.3. 
The relatively low performance regarding ciprofloxacin presented in Table 2 (94.3% correct 
results), was mainly caused by the five laboratories mentioned above (#18, #38, #40, #54 and 
#56). In addition, when performing disk diffusion, the issue regarding the low cut-off value for 
ciprofloxacin is addressed in the protocol ‘Salmonella strains resistant to nalidixic acid should 
also be interpreted as resistant to ciprofloxacin’. These guidelines appear to have been followed 
by all laboratories performing disk diffusion for AST except one (#40).  
For the E. coli reference strain, the obtained results were in general in agreement with the CLSI 
recommendations. The number of laboratories performing AST on Salmonella by the use of 
disk diffusion was six. Five of these uploaded data for the testing of the reference strain with a 
total of 100% within range. For the laboratories performing AST on Salmonella by an MIC-
method, all laboratories uploaded QC-results to the database. The proportion of values within 
the expected range was 98.4%.  
Laboratories #15, #18, #39, #40 and #41 which had a deviation level above the acceptance limit 
in EQAS 2010 with values of 11%, 8.5%, 11%, 13.4% and 7.3% in 2010, respectively, have 
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increased their performance considerably with 4.8%, 2.7%, 2.6%, 7.7% and 1.3% deviations, 
respectively, in the 2011-iteration. 
ESBL-producing Salmonella test strains 
ESBL-producing microorganisms are an emerging problem worldwide, and it should be of a 
high priority for the NRLs to be able to detect them. It was therefore decided at the EURL-AR 
Workshop in June 2008, that the detection of ESBL-producing test strains should be included 
as a mandatory test in this EQAS. 
Four of the Salmonella test strains were ESBL-producers (S-6.1, S-6.3, S-6.4 and S-6.8), and 
the participants were asked to interpret their results according to the description in the protocol. 
Of the 34 laboratories which tested Salmonella, two one not submit results for confirmatory 
testing of ESBL-production which resulted in an evaluation as incorrect. The 33 laboratories 
which uploaded results exhibited in all eight incorrect interpretations, consisting of both false 
positive and false negative results with the overall proportion of laboratories correctly 
confirming S-6.1, S-6.3, S-6.4 and S-6.8 as ESBL- or ampC-producers being 94%, 94%, 94% 
and 88%, respectively. 
Comparison of obtained results when performing confirmatory tests by either of the two 
methods: measurement of inhibition zone diameters (disk diffusion) or by obtaining a MIC-
ratio (E-test) does not show indication of differences for the confirmation on ESBL-production.  
Laboratories #21, #26 and #56 failing to detect the strains S-6.1, S-6.2 and S-6.4, respectively, 
as ESBL-producers could be attributed to lack of confirmatory testing in spite of resistant 
screening results (#21 and #56) and a switch of strains in the laboratory (#26). 
The laboratories #38, #39 and #41 which failed to detect S-6.8 as an ampC-producer all found 
the test strain resistant to the respective cephalosporin(s) but did not submit results for 
cefoxitin. No indication was seen that there was a reaction to the detected cephalosporin 
resistance.  
In the two occasions where the ampC-producer, S-6.8, was incorrectly confirmed as an ESBL-
producer (laboratories #4 and #22), the strain was at the same time correctly confirmed as an 
ampC-producer. Both screening results and results from confirmatory testing were as expected. 
In general, it is recommended that more than one cephalosporin is used for the detection of an 
ESBL-producing Salmonella when initially screening the isolate. The cephalosporins 
cefotaxime, cefpodoxime, ceftiofur, ceftriaxone, and ceftazidime were all found useful in 
detecting isolates with ESBL or plasmidic ampC by Aarestrup et. al. (2010), however, 
cefotaxime, cefpodoxime, and ceftriaxone were superior to the other two.  
Laboratory #54 will be contacted for clarification of the absent results.  
4.2 Campylobacter trial  
The overall percentage of correct antimicrobial susceptibility test results of Campylobacter was 
97.5%. The performance varied from no deviations to 25% deviations, with 23 laboratories 
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performing satisfactorily according to the established acceptance ranges. The three laboratories 
(#4, #19, and #39) with deviation levels above 5% were all defined as outliers.  
The deviation levels above 5% appear to be caused by different reasons: The results obtained 
by laboratory #4 are for five of the 13 deviations interpreted incorrectly when applying the 
interpretative criteria given in the protocol (Appendix 4). When assessing the results obtained 
when testing the C. jejuni reference strain, all results are within the QC range, however, for all 
deviating results except one, the obtained MIC is up to four and five folds higher than expected. 
Laboratory #19 incorrectly detected streptomycin resistance in five of the Campylobacter test 
strains, which was also the case in last year’s EQAS for three of the test strains. No reference 
values are available for streptomycin for the C. jejuni reference strain, and it is suggested that 
the laboratory collect information in-house to follow the trend of the MIC of the QC-strain 
towards this antimicrobial. 
Laboratory #39 exhibit a deviation level at 10%. The deviations indicate a possibility that two 
strains have been exchanged by mistake.  
The proportion of results for the C. jejuni reference strain within the QC intervals was 95.8% 
which is a little higher than in EQAS 2010. In this year’s trial, all participating laboratories 
uploaded data from tests performed on the reference strain. The six values outside the QC 
intervals were obtained by five laboratories, of which four performed well (under the 5% 
acceptance level). The remaining one had a deviation level at 17.5% (laboratory #19).  
Laboratories #19, #21, #22, #30 and #44 which had a deviation level above the acceptance limit 
in EQAS 2010 showed values of 10%, 11.1%, 11.4%, 7.5% and 7.5% in 2010, respectively, 
where laboratory #19 exhibits a decrease in performance (to 17.5%), one laboratory did not 
participate in this part of the EQAS this year and the remaining three laboratories (#22, #30 and 
#44) exhibit an improvement to 5%, 0% and 0%, respectively. 
One of the Campylobacter test strains exhibits the rare antimicrobial resistance profile of 
ciprofloxacin resistance and nalidixic acid susceptibility. This strain was isolated from food in 
Denmark and tested at DTU Food with the EURL for Campylobacter at SVA in Sweden kindly 
confirming the species identification. A number of the participants commented on the rare 
phenotype, one laboratory chose not to upload the result for nalidixic acid and four laboratories 
submitted an interpretation as resistant for nalidixic acid/C-6.3; all four obtained MIC values at 
32 or 64 µg/mL. The ciprofloxacin result did not cause any problems (100% correct results).  
4.3 Optional genotypic characterisation 
As the focus on molecular aspects appear to be increasing, it is likely that genotypic 
characterisation of relevant bacterial isolates in the future will gain further interest. The 
genotypic characterisation offered as an optional supplementary part of this EQAS was 
performed by four laboratories. All participating laboratories obtained satisfying results.  
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5. Conclusions 
The goal of the EURL-AR EQAS is to have all participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and Campylobacter with a deviation level below 5%. This 
seems within reach for Salmonella as well as for Campylobacter.  
The performance of the NRL’s appear to be at the same level for Salmonella AST’s in this 
EQAS (98.1%) when compared to the results from the EQAS 2009 and 2010 (98.4% and 
97.8%). Regarding Campylobacter AST’s, the level of deviation also appears to be stable with 
a level at 1.9% in 2011 compared to 2.2% and 2.0% in 2009 and 2010.  
Laboratories which have not yet introduced tests to detect ESBL-producing 
Enterobacteriaceae, should prioritize this area, as these antimicrobial resistance mechanisms 
appear to continue to emerge worldwide. In addition, the genotypic characterisation which was 
offered as an optional supplementary part of this EQAS appeared to be of interested to the 
EURL-AR network, and is likely to be repeated. 
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EQAS 2011 FOR SALMONELLA, CAMPYLOBACTER AND OPTIONAL GENOTYPIC 
CHARACTERISATION  
The EURL-AR are pleased to announce the launch of another EQAS. The EQAS provides the 
opportunity for proficiency testing, which is considered an important tool for the production of 
reliable laboratory results of consistently good quality. 
This EQAS offers antimicrobial susceptibility testing of eight Salmonella isolates, eight 
Campylobacter isolates and two strains for genotypic characterisation (one Salmonella spp. and one 
MRSA). Additionally, new participants will be offered the following QC strains: E. coli ATCC 
25922 (CCM 3954) and C. jejuni ATCC 33560 (CCM 6214).  
This EQAS is specifically for NRL’s on antimicrobial resistance. Therefore, laboratories designated 
to be NRL-AR do not need to sign up to participate but are automatically regarded as participants. 
Participation is free of charge for all designated NRL-AR’s.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
Please remember to provide the EQAS coordinator with documents or other information that can 
simplify customs procedures (eg. specific text that should be written on the invoice). As means of 
avoiding passing the deadline we ask you to send us this information already at this stage. For your 
information, the content of the parcel is “Biological Substance Category B”. 
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol
 
: The isolates will be shipped in October 2011. The protocol will 
be available on the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December 16th
 
 2011 via the password-protected website. Upon reaching the deadline, each 
participating laboratory is kindly asked to enter the password-protected website once again to 
download an automatically generated evaluation report.  
EQAS report
 
: When the EQAS is concluded, the data will be collected in an overall report in which 
it is possible to see all participants’ results in comparison. In the report the laboratories will be 
coded, which ensures full anonymity; only the National Food Institute and the EU Commission will 
be given access to un-coded results. 
Next EQAS
Please contact me if you have comments or questions regarding the EQAS. 
: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be performed in June 2012.  
Sincerely, 
 
Susanne Karlsmose (EQAS-Coordinator) 
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Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X - Austrian Agency for Health and Food Safety Austria
X X - Institute of Public Health Belgium
X - - Nacional Diagnostic and Research Veterinary Institute Bulgaria
X - - Croatian Veterinary Institut Croatia
X X - Veterinary Services Cyprus
X X - State Veterinary Institute Praha Czech Republic
X X X The National Food Institute Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X - Finnish Food Safety Authority EVIRA Finland
X - - ANSES Maisons Alfort France
- X - ANSES Ploufragan France
X - - ANSES Lyon France
X - - ANSES Fougères France
X X X Federal Institute for Risk Assessment Germany
X - - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office, Veterinary Diagnostical Directorate Hungary
X X - Central Veterinary Research Laboratory Ireland
X - - Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X - Institute of Food Safety, Animal Health and Environment „BIOR” Latvia
X X - National Food and Veterinary Risk Assessment Institute Lithuania
X X - Public Health Laboratory Malta
X X - Food and Consumer Product Safety Authority (VWA) Netherlands
X X X Central Veterinary Institute of Wageningen UR Netherlands
X X - Veterinærinstituttet Norway
X X - National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria Portugal
X X X National Institute of Research-Development for Microbiology and Immunology “Cantacuzino” Romania
X X - Institute for Hygiene and Veterinary Public Health Romania
X (X) - Institute of Veterinary Medicine of Serbia Serbia
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
- - - Laboratorio Central de Sanidad, Animal de Santa Fe (only Staph) Spain
X X X Laboratorio Central de Sanidad, Animal de Algete Spain
X X - VISAVET Health Surveillance Center, Complutense University Spain
X - - Centro nacional de Alimentacion. Agencia Espanola de Seguridad Alimentria y Nutricio Spain
X X X National Veterinary Institute, SVA Sweden
X X X Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland
X X - The Veterinary Laboratory Agency United Kingdom
X X - Centre for Infections Health Protection Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enroled by the EURL
Not a Member State of the EU
Appendix 3a, page 1 of 1
Salmonella  test strains and reference values (MIC-value and interpretation)
Ampicillin Cefotaxime ESBL Ceftazidime ESBL Cefoxitin Ceftiofur Chloramphenicol Ciprofloxacin Gentamicin Imipenem Nalidixic acid Streptomycin Sulfamethoxazole Tetracycline Trimethoprim
AMP CTX CTX:CTX/Cl CAZ CAZ:CAZ/Cl XNL CHL CIP GEN IMI NAL STR SMX TET TMP
EURL S-6.1  > 32 RESIST > 4 RESIST >8 / phantom  = 8 RESIST >8 / phantom  <= 4 SUSC  > 8 RESIST  = 4 SUSC  = 0.06 SUSC  = 1 SUSC <= 0.5 SUSC  = 4 SUSC  = 16 SUSC  = 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-6.2  > 32 RESIST <= 0.12 SUSC  = 0.25 SUSC  <= 0.5 SUSC  = 64 RESIST  = 0.25 RESIST  = 1 SUSC  > 64 RESIST  = 32 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST
EURL S-6.3  > 32 RESIST > 4 RESIST  >8  = 128 RESIST  >8  <= 4 SUSC  > 8 RESIST  = 64 RESIST  = 0.25 RESIST  > 16 RESIST <= 0.5 SUSC  = 8 SUSC  > 128 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST
EURL S-6.4  > 32 RESIST > 4 RESIST  >8  = 1 SUSC <8  <= 4 SUSC  > 8 RESIST  = 4 SUSC  = 0.5 RESIST  = 1 SUSC <= 0.5 SUSC  > 64 RESIST  = 16 SUSC  = 64 SUSC  > 32 RESIST <= 1 SUSC
EURL S-6.5 <= 1 SUSC <= 0.12 SUSC  = 0.12 SUSC  = 1 SUSC  = 4 SUSC  = 0.03 SUSC  = 0.5 SUSC  = 4 SUSC  = 16 SUSC  = 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-6.6 <= 1 SUSC <= 0.12 SUSC  = 0.25 SUSC  = 1 SUSC  = 4 SUSC  = 0.03 SUSC  = 1 SUSC  = 4 SUSC  = 32 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST
EURL S-6.7 <= 1 SUSC <= 0.12 SUSC  = 0.5 SUSC  = 1 SUSC  = 8 SUSC  = 0.25 RESIST  = 0.5 SUSC  = 8 SUSC  = 16 SUSC  = 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-6.8  > 32 RESIST > 4 RESIST <8 / ND  = 16 RESIST <8 / ND  = 32 RESIST  > 8 RESIST  > 64 RESIST  = 0.03 SUSC  = 1 SUSC <= 0.5 SUSC  = 4 SUSC  > 128 RESIST  > 1024 RESIST  > 32 RESIST <= 1 SUSC
Resistant
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Chloramphenicol Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CHL CIP ERY GEN NAL STR TET
C. jejuni EURL C-6.1 <= 2 SUSC  = 0.12 SUSC  = 0.5 SUSC  = 0.25 SUSC  = 4 SUSC  <= 1 SUSC  = 0.25 SUSC
C. jejuni EURL C-6.2  = 4 SUSC  = 0.12 SUSC  = 1 SUSC  = 0.25 SUSC  = 4 SUSC  <= 1 SUSC  = 64 RESIST
C. jejuni EURL C-6.3  = 4 SUSC  = 8 RESIST  = 0.5 SUSC  = 0.125 SUSC  <= 2 SUSC  <= 1 SUSC  = 0.5 SUSC
C. jejuni EURL C-6.4  = 4 SUSC  = 8 RESIST  = 1 SUSC  = 0.125 SUSC  > 64 RESIST  <= 1 SUSC  = 32 RESIST
C. coli EURL C-6.5  = 8 SUSC  = 64 RESIST  > 64 RESIST  = 0.25 SUSC  > 64 RESIST  <= 1 SUSC  > 64 RESIST
C. coli EURL C-6.6  = 4 SUSC  = 16 RESIST  = 1 SUSC  = 0.5 SUSC  > 64 RESIST  = 4 SUSC  = 0.25 SUSC
C. coli EURL C-6.7  = 4 SUSC  = 0.12 SUSC  > 64 RESIST  = 0.5 SUSC  = 4 SUSC  = 2 SUSC  = 0.25 SUSC
C. coli EURL C-6.8  = 8 SUSC  = 0.06 SUSC  > 64 RESIST  = 0.5 SUSC  = 8 SUSC  > 16 RESIST  = 0.25 SUSC
Resistant
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EURL-AR External Quality Assurance System 2011 
- Salmonella, Campylobacter and optional genotypic characterisation  
 
Id: «Lab_no» 
«Institute» 
«Country»     
Kgs. Lyngby, October 2011 
 
Dear «Name», 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2011.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-AR 
EQAS are available: 
- Protocol for Salmonella and Campylobacter including test forms 
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Strains 
 
We ask you to examine the eight Salmonella and the eight Campylobacter strains that we send to 
you by performing antimicrobial susceptibility testing. Participants receiving the additional strains, 
EURL GEN 3.1 and EURL GEN 3.2, have the option to characterise them genotypically. In the 
protocol you will find detailed description of how to test the strains. Additionally, you will find a 
description of how to enter your results into the interactive web database. For entering data you 
need this username and password. 
 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
After receipt, the strains should be stored dark and at 4°C for stabs, and dark and cool for freeze-
dried strains. Charcoal swabs must be subcultured straight away.  
 
The results should be returned to us no later than December 16th
 
, 2011. 
Please acknowledge receipt of parcel immediately on arrival (by email to suska@food.dtu.dk). For 
further information, please do not hesitate to contact us. 
 
Yours sincerely, 
 
Susanne Karlsmose 
EQAS-Coordinator 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2011 
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PROTOCOL  
For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional 
genotypic characterisation of two test strains 
 
 
1 INTRODUCTION    ................................................................................................................. 1
2 OBJECTIVES    ....................................................................................................................... 2
3 OUTLINE OF THE EQAS 2011    ......................................................................................... 2
3.1 Shipping, receipt and storage of strains    ..................................................................... 2
3.2 Suggested procedure for reconstitution of the lyophilised reference strains    ......... 2
3.3 Susceptibility testing    .................................................................................................... 2
3.4 Optional genotypic characterisation    .......................................................................... 5
4 REPORTING OF RESULTS AND EVALUATION    ......................................................... 8
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE   ........................... 9
 
 
1 INTRODUCTION 
One of the tasks as the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR) is to 
organise and conduct an External Quality Assurance System (EQAS) on antimicrobial susceptibility 
testing (AST) of Salmonella and Campylobacter. The Salmonella and Campylobacter EQAS 2011 
will include susceptibility testing of eight Salmonella and eight Campylobacter strains together with 
susceptibility testing of the reference strains E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 
33560 (CCM 6214). Additionally, optional PCR-testing of a selected Gram-negative isolate and a 
selected Gram-positive isolate is offered. 
For new participants of the EURL-AR network who have not already received the mentioned 
reference strains, these are included in the parcel. The reference strains will not be included in the 
years to come. The reference strains are original certified cultures and are free of charge. Please take 
proper care of the strains. Handle and maintain them as suggested in the manual ‘Subculture and 
Maintenance of QC Strains’. Please use them for future internal quality control for susceptibility 
testing in your laboratory.  
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For this EQAS, members of the Food- and Waterborne Diseases and Zoonoses Programme (FWD) 
based at ECDC are also participating, however for these participants the EQAS has been slightly 
adjusted. Description of this can be found in this protocol, i.e. that QC reference strains are not 
offered, and that for antimicrobial susceptibility testing (AST) of Campylobacter, results obtained 
by in-house methods like disk diffusion or E-test are also accepted. 
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of susceptibility testing of pathogens originating from food and animal sources, especially 
Salmonella and Campylobacter. Furthermore, to assess and improve the comparability of 
surveillance and antimicrobial susceptibility data reported to EFSA by different laboratories on 
Salmonella and Campylobacter and to harmonise the breakpoints used within the EU. 
3 OUTLINE OF THE EQAS 2011 
3.1 Shipping, receipt and storage of strains 
In October 2011, the EU appointed National Reference Laboratories will receive a parcel from the 
National Food Institute containing eight Salmonella, eight Campylobacter strains and two additional 
strain(s) for optional PCR (one Salmonella and one Staphylococcus). Reference strains will be 
included for participants who have not previously received these. There might be ESBL-producing 
strains among the selected material.  
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be kept refrigerated until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below.  
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
Please see the document ‘Instructions for opening and reviving lyophilised cultures’ on the EURL-
AR-website (see www.eurl-ar.eu). 
3.3 Susceptibility testing 
The strains should be susceptibility tested towards as many as possible of the following 
antimicrobials by the method used in the laboratory when performing monitoring for EFSA. For 
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MIC the cut off values listed in Tables 1 and 2 should be used. The epidemiological cut-off values 
allow two categories of characterisation – resistant or sensitive.  
Participants using disk diffusion are recommended to interpret the results according to their 
individual breakpoints, categorising them into the terms resistant and susceptible. A categorization 
as intermediary is not accepted; therefore intermediary results should be interpreted as 
susceptible. Interpretations in concordance with the expected value will be categorised as ‘correct’, 
whereas interpretations that deviate from the expected interpretation will be categorised as 
‘incorrect’.  
The cut off values used in the interpretation of the MIC results are developed by EUCAST 
(www.eucast.org). 
With regard to MIC range and/or disc content we ask you to fill in these pieces of information in the 
database. Also, if you do not use
 
 the cut-off values listed in the protocol for interpretation of the 
susceptibility results, please fill in or update the breakpoints used, in the database. 
3.3.1 Salmonella. 
Testing of gentamicin and streptomycin
Antimicrobials for Salmonella 
 may be of value for monitoring. Please, do not take into 
account in this study, that the CLSI guidelines state that for aminoglycosides Salmonella should not 
be reported as susceptible. 
MIC (µg/mL) 
R is > 
Ampicillin (AMP) 8 
Cefotaxime (CTX) 0.5 
Ceftazidime (CAZ)** 2 
Ceftiofur (XNL)** 2 
Chloramphenicol (CHL) 16 
Ciprofloxacin (CIP) 0.06 
Gentamicin (GEN) 2 
Nalidixic acid (NAL) 16 
Streptomycin (STR) 16 
Sulphonamides (SMX)* 256 
Tetracycline (TET) 8 
Trimethoprim (TMP) 2 
Table 1: Interpretative guidelines for Salmonella  
* CLSI     
** Not part of the EFSA monitoring programme (used for confirmatory tests for ESBL production) 
 
Also, when following EUCAST epidemiological cut-off values, Salmonella resistant to nalidixic 
acid should also be interpreted as resistant to ciprofloxacin. When using disc diffusion and CLSI 
Appendix 4b, page 3 of 10
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2011 
 
 
Page 4 of 10 
DFVF- M00-06-001/24.10.2011 
clinical breakpoints this connection between nalidixic acid and ciprofloxacin is not taken into 
account. Thus, the result in this situation with regard to ciprofloxacin will deviate from the expected 
result in this EQAS. 
Important notes: beta-lactam resistance
Confirmatory tests for ESBL production is mandatory on all strains resistant to cefotaxime (CTX), 
ceftazidime (CAZ) and/or ceftiofur (XNL). 
: 
Confirmatory test for ESBL production requires use of both cefotaxime (CTX) and ceftazidime 
(CAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (E-test 3 dilution steps difference; 
MIC CTX : CTX/CL or CAZ : CAZ/CL ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone diameter for 
either antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone 
(CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
Confirmatory test for Metallo-beta-lactamase (MBL) production requires use of imipenem (IMI) 
and IMI/EDTA. Synergy is defined as a ≥ 3 twofold concentration decrease in the MIC for the 
combination IMI/EDTA vs. MIC for IMI alone (E-test 3 dilution steps difference, MIC IMI : 
IMI/EDTA ratio ≥ 8; CLSI M100, Table 2A; Enterobacteriaceae). The presence of synergy indicates 
MBL production. 
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that should be verified by PCR and sequencing. 
The EURL-AR aims to harmonise with EUCAST expert rules. Accordingly, MIC values and 
relative interpretation of cefotaxime, ceftazidime and/or ceftiofur used for detection of beta-
lactamase-producing strains in this EQAS should be reported as found.  
 
3.3.2 Campylobacter   
Please find information on the test forms showing which test strains are C. jejuni and C. coli, 
respectively. 
For AST of Campylobacter only MIC methods are recommendable, i.e. broth or agar dilution 
methods. The EURL-AR does not recommend the use of either disk diffusion or E-test for AST of 
Campylobacter. Laboratories in the EURL-AR network should test the sub-cultured Campylobacter 
by the use of microbroth or agar dilution using incubation at 36-37ºC for 48 hours or 42ºC for 24 
hours.  
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Antimicrobials for Campylobacter MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
 C. jejuni C. coli 
Chloramphenicol* 16 16 
Ciprofloxacin 1 1 
Erythromycin 4 16 
Gentamicin 1 2 
Nalicixic acid* 16 32 
Streptomycin 2 4 
Tetracycline 2 2 
Table 2: Interpretative guidelines for Campylobacter  
*Not part of the EFSA monitoring programme 
  
 
For the laboratories of the FWD-network, results of AST of Campylobacter may be obtained by in-
house methods like disk diffusion or E-test. In this case, in-house interpretative criteria must be 
applied. 
 
3.4 Optional genotypic characterisation 
An optional PCR-testing of a selected S. aureus (EURL GEN 3.1) as well as a Salmonella (EURL 
GEN 3.2) isolate is offered. If performing the genotypic characterisation of these test strains, the 
results requested are the genes harboured in the test strain. The genes listed in Tables 3 and 4 are 
those included in the test. The test strains may harbour resistance genes not present on these lists; 
these will not be evaluated by the database, but may be mentioned in the comments-field. When 
uploading the results in the database, the identified genes will be evaluated against the expected 
results. The results will be evaluated on the actual gene identified. The groups of TEM-, CTX-, 
SHV-, CMY-, OXA-genes as well as the gyrA-mutations and parC-mutations will additionally be 
evaluated on the group selected. For gyrA and parC the codon-no of the site of mutation will be 
evaluated in the same way as the genes. 
The method used for the PCR-testing should be the one(s) used in your laboratory. The expected 
results listed in the database are those obtained by the EURL-AR.  
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Antimicrobial Gene 
Aminoglycosides addD 
 aphA3 
 aacA-aphD 
 aadE 
Betalactamases blaI 
 blaR 
 blaZ 
 mecA 
Chloramphenicol cat 
Glycopeptides vanA 
 vanB 
 vanZ 
Lincosamides lnu(A) 
Macrolides erm(A) 
 erm(B) 
 erm(C) 
 mef(A) 
 mph(C) 
 msr(A) 
Quarternary ammonium compounds qacA 
Steroid antibacterial far1 
Streptogramin vat(A) 
 vat(B) 
 vga(A) 
 vgB(A) 
Streptothricin sat 
Tetracycline tet(K) 
 tet(M) 
 tet(O) 
Trimethoprim dfrA 
Table 3: Genes included in the test of the S. aureus-strain (EURL GEN 3.1) 
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Antimicrobial Group Gene/Codon no. 
Betalactams TEM List of gene numbers in the database 
 CTX List of gene numbers in the database 
 SHV List of gene numbers in the database 
 CMY List of gene numbers in the database 
 OXA List of gene numbers in the database 
Chloramphenicol - cmlA 
 - catA1 
Florphenicol - floR 
Gentamicin - aac(3)-IV 
 - ant(2")-I 
 - aac(3)-II 
Neomycin - aph(3’)-III 
 - aph(3’)-II 
 - aph(3’)-I 
Quinolones gyrA Codon 83 
 gyrA Codon 87 
 parC Codon 57 
 parC Codon 78 
 parC Codon 80 
 parC Codon 84 
 - qnrA 
 - qnrB 
 - qnrC 
 - qnrD 
 - qnrS 
Streptomycin - strA 
 - strB 
 - aadA 
Sulfonamides - sul1 
 - sul2 
 - sul3 
Tetracycline - tetA 
 - tetB 
 - tetC 
 - tetD 
 - tetE 
 - tetF 
 - tetG 
Table 4: Genes included in the test of the Salmonella-strain (EURL GEN 3.2) 
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4 REPORTING OF RESULTS AND EVALUATION 
Test forms are available for recording your results before you enter them into the interactive web 
database. We kindly ask you to report in the database the tested MIC range and/or antimicrobial disk 
content. If you did not 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than 16th December 2011. 
use the cut-off values recommended in the protocol for interpretation of 
AST results, please report the breakpoints used. 
After 
the deadline, the database will be closed and you will be able to view and print an automatically 
generated report evaluating your results.
If you do not have access to the Internet, or if you experience difficulties in entering your results, try 
a few days later or, alternatively, return the completed test forms by e-mail, fax or mail to the 
National Food Institute, Denmark.  
 Results in agreement with the expected interpretation are 
categorised as ‘correct’, while results deviating from the expected interpretation are categorised as 
‘incorrect’. 
All results will be summarised in reports available to all participants. The data will be collected in 
an overall summary report in which anonymous laboratory results will be analyzed. This summary 
report will focus on comparing the results from the EURL-AR network, and public health 
laboratories (FWD-laboratories) to assess the level of harmonization need.    
In addition, separate reports for the EURL-AR network (by DTU) and for public health laboratories 
(by ECDC) will be prepared.  
The data in the report will be presented with laboratory codes. A laboratory code is only known to 
the individual laboratory, while the complete list of laboratories and their respective codes is 
confidential and only known to the EURL-AR (all participants), the ECDC (FWD-laboratories) and 
the EU Commission (NRL-ARs). All conclusions and all three reports will be publicly available.  
If you have any questions, please do not hesitate to contact the EQAS Coordinator: 
 
Susanne Karlsmose 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
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5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read this passage before entering the web page. Before you go ahead, you need your test form 
by your side together with your breakpoint values.  
You are able to browse back and forth by using the forward and back keys or click on the EURL 
logo. 
You enter the EURL-AR EQAS web page (http://thor.dfvf.dk/crl) then write your username and 
password in low cases and press enter. Your username and password is the same as in the previous 
EQAS’s arranged by the National Food Institute. If you have problems with the login please contact 
us. 
Click on either “Salmonella test results” or “Campylobacter test results” depending on your results. 
The below description is aimed at Salmonella entry but is exactly the same as for Campylobacter 
entry. 
Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method you have used for the susceptibility testing of Salmonella and the brand 
of discs, tablets, MIC trays etc.  
Fill in the relevant information, either disk content or MIC range. If you use disk diffusion, please 
upload the breakpoints used. 
You will find one more box to fill in on this page when testing Campylobacter: Fill in the actual 
incubation condition used for susceptibility testing of Campylobacter – 36°C/48h or 42°C/24h. 
Click on "save and go to next page”  
In the data entry pages for each Salmonella and Campylobacter strain, you enter the obtained value 
and the interpretation as R or S. 
For Salmonella, you also type in results for the ESBL tests. 
If you have not used an antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains please enter the zonediameters in mm or MIC values 
in µg/ml. Remember to use the operator keys to show e.g. equal to, etc. If you do not use CLSI 
guidelines for AST on the reference strains, please add a comment on the method used. 
Click on "save and go to next page" 
This page is a menu, from where you can review the input pages, approve your input and finally see 
and print the evaluated results: 
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Browse through the pages and make corrections if necessary. Remember to save a page if you make 
any corrections. If you save a page without changes, you will see an error screen, and you just have 
to click on "back" to get back to the page and "go to next page" to continue. 
Please fill in the evaluation form. 
Approve your input. Be sure that you have filled in all the results before approval, as  YOU CAN 
ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database, but 
allows you to see the evaluated results.   
If you have performed the optional genotypic characterisation: 
Click on “Gene test” and follow the description in the database for upload of the optional PCR 
results. Approve your input. Be sure that you have filled in all the results before approval. The 
approval blocks your data entry in the interactive database, but allows you to see the evaluated 
results. 
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Salmonella and Campylobacter, genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
EU Community Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2011 
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TEST FORM                                                            
 
Does your laboratory have an accreditation for Salmonella AST?   Yes     No 
 
Does your laboratory have an accreditation for other laboratory methods/tests?   Yes    No 
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  Broth Microdilution    
  Agar dilution 
  E-test (strips)                                       
  Disk diffusion (paper disks)  
  Rosco Neo Sensitabs (tablets)            
 
Brand of microdilution plate, strips or disks:       
 
Method used for detection of ESBL-producing strains, see pictures of the methods on 
http://www.eurl-ar.eu/201-resources.htm  
 
  E-test 
  Double disk 
  Combination disk                                       
  MIC determination (microbroth)  
  Selective media please specify:       
  Other, please specify        
 
Comments or additional information:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM          
 
Breakpoints used (zonediameters) and general info regarding disk content and test-range 
used for MIC: 
 
- Please fill in the disk content or the test-range used for MIC, respectively. 
- Please, only fill in breakpoints if you did not use a MIC method, that is, only if you used other 
breakpoints/cut-off values than the ones listed in the protocol for interpretation of AST results for 
Salmonella. Otherwise leave breakpoint fields empty. 
                                                   
 
 
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
filled in 
 
Zonediameter (mm) 
 
Please, only fill in breakpoint information if 
you did not use the cut-off values listed in 
the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
 
Ampicillin, AMP             ≤             ≥       
Cefotaxime, CTX             ≤             ≥       
Ceftazidime, CAZ             ≤             ≥       
Ceftiofur, XNL             ≤             ≥       
Chloramphenicol, CHL             ≤             ≥       
Ciprofloxacin, CIP             ≤             ≥       
Gentamicin, GEN             ≤             ≥       
Nalidixic acid, NAL             ≤             ≥       
Streptomycin, STR             ≤             ≥       
Sulphamethoxazole, SMX             ≤             ≥       
Tetracycline, TET             ≤             ≥       
Trimethoprim, TMP               ≤             ≥       
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM                                                            
 
Does your laboratory have an accreditation for Campylobacter AST?  Yes     No 
 
Does your laboratory have an accreditation for other laboratory methods/tests?  Yes     No 
 
Incubation conditions:     36-37ºC / 48h   42ºC / 24h 
 
Method used for antimicrobial susceptibility testing of Campylobacter in this EQAS:: 
 Microbroth 
 Agardilution 
 In-house (disk diffusion) 
 In-house (E-test) 
 
Brand of broth/agar:       
Additional comments:       
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
 
If using an in-house method (disk diffusion or E-test), 
- Please fill in the disk content or the test-range used for E-test, respectively. 
- Please fill in interpretative criteria if you used other breakpoints/cut-off values than the ones listed 
in the protocol for interpretation of AST results for Campylobacter. Otherwise leave breakpoint 
fields empty. 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
filled in 
 
Zonediameter (mm) 
 
Please, only fill in breakpoint information if 
you did not use the cut-off values listed in 
the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
 
Chloramphenicol             ≤             ≥       
Ciprofloxacin             ≤             ≥       
Erythromycin             ≤             ≥       
Gentamicin             ≤             ≥       
Nalidixic Acid             ≤             ≥       
Streptomycin             ≤             ≥       
Tetracycline             ≤             ≥       
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TEST FORM  
Strain  
 
 
Antimicrobial  
Interpretation 
 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Salmonella 
EURL S-6.X 
 
 
Ampicillin, AMP     
  
         
   Cefotaxime, CTX     
  
         
   Ceftazidime, CAZ     
  
         
   Ceftiofur, XNL     
  
         
   Chloramphenicol, CHL     
  
         
   Ciprofloxacin, CIP     
  
         
   Gentamicin, GEN     
  
         
   Nalidixic acid, NAL     
  
         
   Streptomycin, STR     
  
         
   Sulfonamides, SMX     
  
         
   Tetracycline, TET     
  
         
   Trimethoprim, TMP     
  
         
    
All strains resistant against cefotaxime (CTX), ceftazidime (CAZ) or ceftiofur (XNL) should be 
included for confirmatory tests for ESBL production.  
See further description of confirmatory tests above in section ‘3.3.1 Salmonella’. 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio    
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam   
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
CAZ/CL : CAZ mic ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam  
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
Cefoxitin, FOX mic value   MIC value > 16   MIC value ≤ 16  Zone diameter  
 D ≤ 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value ≤ 1 
 Confirmed ESBL 
 Confirmed AmpC 
 Confirmed Metallo betalactamase IMI/E : IMI mic ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
Comments:      
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM                                                            
 
Susceptibility testing of E. coli referencestrain ATCC 25922 
 
Strain 
 
 
 
Antimicrobial  
 
Zonediameter (mm) or  
MIC-value (μg/ml) 
E. coli ATCC 25922 
 
 
 
 
Ampicillin, AMP       
Cefotaxime, CTX       
Cefoxitin, FOX       
Ceftazidime, CAZ       
Ceftiofur, XNL       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Gentamicin, GEN       
Imipenem, IMI       
Nalidixic acid, NAL       
Streptomycin, STR       
Sulfisoxazole, FIS*       
Tetracycline, TET       
Trimethoprim, TMP       
 
*The antimicrobial which is mentioned in the CLSI M100 performance standard as a representative 
for the sulfonamides as regards acceptable limits for quality control strains (CLSI M100, Table 3) 
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TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-6.1 
 
C. jejuni 
 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-6.2 
 
C. jejuni 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-6.3 
 
C. jejuni 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-6.4 
 
C. jejuni 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
EU Community Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2011 
 
 
Appendix 4c, page 8 of 9 
Page 8 of 9 
DFVF- M00-06-001/24.10.2011 
 
TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Nalidixic Acid             
Tetracycline             
 
 
  
For Agar dilution: 
 
 Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
 
C. jejuni ATCC 33560 
 
 
Ciprofloxacin       
 
Doxycycline        
 
Erythromycin        
 
Gentamicin       
Meropenem        
Nalidixic Acid        
Tetracycline       
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TEST FORM – genotypic characterisation                                                           
 
Genotypic characterisation of the test strains 
 
EURL GEN 3.X PCR-method used 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
 
Comments:       
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
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 Periodically perform colony counts to check the inoculum preparation procedure 
 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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DAILY MIC QC CHART 
 
Reference: CLSI M7-A8, page 44 
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WEEKLY MIC QC CHART 
 
 
Reference: CLSI M7-A8, page 45 
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Disk content and breakpoints used in daily routine (disk diffusion) - Salmonella
Antimicrobial Lab No Disk content 
(ug)
R <= (mm) I  = (mm) S >= (mm)
Ampicillin, AMP 15 25 13 14-20 21
Ampicillin, AMP 18 10 13 14-16 17
Ampicillin, AMP 38 10 13 14-16 17
Ampicillin, AMP 40 10 13 14-16 17
Cefotaxime, CTX 15 30 22 23-25 26
Cefotaxime, CTX 18 30 22 23-25 26
Cefotaxime, CTX 38 30 22 23-25 26
Cefotaxime, CTX 40 30 14 15-22 23
Ceftazidime, CAZ 15 30 18 19-25 26
Ceftazidime, CAZ 18 30 17 18-20 21
Ceftazidime, CAZ 40 30 14 15-17 18
Ceftiofur, XNL 15 30 17 18-20 21
Ceftiofur, XNL 18 30
Ceftiofur, XNL 40 30 14
Chloramphenicol, CHL 15 30 18 19-21 22
Chloramphenicol, CHL 18 30 12 13-17 18
Chloramphenicol, CHL 38 30 12 13-17 18
Chloramphenicol, CHL 40 30 12 13-17 18
Ciprofloxacin, CIP 15 16 17-21 22
Ciprofloxacin, CIP 18 5 15 16-20 21
Ciprofloxacin, CIP 38 5 15 16-20 21
Ciprofloxacin, CIP 40 5 15 16-20 21
Gentamicin, GEN 15 15 15 16-17 18
Gentamicin, GEN 18 10 12 13-14 15
Gentamicin, GEN 38 10 12 13-14 15
Gentamicin, GEN 40 10 12 13-14 15
Nalidixic acid, NAL 15 30 14 15-19 20
Nalidixic acid, NAL 18 30 13 14-18 19
Nalidixic acid, NAL 38 30 13 14-18 19
Nalidixic acid, NAL 40 30 13 14-18 19
Streptomycin, STR 15 10  UI 12 13-14 15
Streptomycin, STR 18 10 11 12-14 15
Streptomycin, STR 38 10 11 12-14 15
Streptomycin, STR 40 10 11 12-14 15
Sulfamethoxazole, SMX 15 200 11 12-16 17
Sulfamethoxazole, SMX 18 300 12 13-16 17
Sulfamethoxazole, SMX 40 300 12 13-16 17
Tetracycline,TET 15 30 UI 16 17-18 19
Tetracycline,TET 18 30 11 12-14 15
Tetracycline,TET 38 30 11 12-14 15
Tetracycline,TET 40 30 11 12-14 15
Trimethoprim, TMP 15 5 11 12-15 16
Trimethoprim, TMP 18 5 10 11-15 16
Trimethoprim, TMP 38 5 10 11-15 16
Trimethoprim, TMP 40 5 10 11-15 16
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Test results from the reference strain E. coli ATCC 25922
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method
1 Ampicillin, AMP = 4 2 8 1 MIC
1 Cefotaxime, CTX <= 0.12 0,03 0,125 1 MIC
1 Ceftiofur, XNL <= 0.5 0,25 1 1 MIC
1 Chloramphenicol, CHL = 4 2 8 1 MIC
1 Ciprofloxacin, CIP <= 0.015 0,004 0,016 1 MIC
1 Gentamicin, GEN <= 0.5 0,25 1 1 MIC
1 Nalidixic acid, NAL <= 4 1 4 1 MIC
1 Streptomycin, STR <= 8 4 16 1 MIC
1 Tetracycline, TET <= 2 0,5 2 1 MIC
1 Trimethoprim, TMP <= 1 0,5 2 1 MIC
2 Ampicillin, AMP = 2 2 8 1 MIC
2 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
2 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
2 Chloramphenicol, CHL = 4 2 8 1 MIC
2 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
2 Gentamicin, GEN = 0.5 0,25 1 1 MIC
2 Nalidixic acid, NAL <= 4 1 4 1 MIC
2 Streptomycin, STR = 8 4 16 1 MIC
2 Sulfisoxazole, FIS = 16 8 32 1 MIC
2 Tetracycline, TET <= 1 0,5 2 1 MIC
2 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
4 Ampicillin, AMP = 2 2 8 1 MIC
4 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
4 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
4 Chloramphenicol, CHL = 4 2 8 1 MIC
4 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
4 Gentamicin, GEN = 0.5 0,25 1 1 MIC
4 Nalidixic acid, NAL = 4 1 4 1 MIC
4 Streptomycin, STR = 8 4 16 1 MIC
4 Sulfisoxazole, FIS = 16 8 32 1 MIC
4 Tetracycline, TET = 1 0,5 2 1 MIC
4 Trimethoprim, TMP = 1 0,5 2 1 MIC
6 Ampicillin, AMP = 4 2 8 1 MIC
6 Cefotaxime, CTX < 0.06 0,03 0,125 1 MIC
6 Ceftazidime, CAZ < 0.25 0,06 0,5 1 MIC
6 Chloramphenicol, CHL = 4 2 8 1 MIC
6 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
6 Gentamicin, GEN < 0.25 0,25 1 1 MIC
6 Nalidixic acid, NAL < 4 1 4 1 MIC
6 Streptomycin, STR = 4 4 16 1 MIC
6 Tetracycline, TET < 1 0,5 2 1 MIC
6 Trimethoprim, TMP < 0.5 0,5 2 1 MIC
9 Ampicillin, AMP = 4 2 8 1 MIC
9 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
9 Cefoxitin, FOX = 4 2 8 1 MIC
9 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
9 Ceftiofur, XNL = 0.5 0,25 1 1 MIC
9 Chloramphenicol, CHL = 4 2 8 1 MIC
9 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
9 Gentamicin, GEN = 0.5 0,25 1 1 MIC
9 Imipenem, IMI = 0.12 0,06 0,25 1 MIC
9 Nalidixic acid, NAL = 4 1 4 1 MIC
9 Streptomycin, STR = 8 4 16 1 MIC
9 Sulfisoxazole, FIS = 16 8 32 1 MIC
9 Tetracycline, TET = 1 0,5 2 1 MIC
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9 Trimethoprim, TMP = 1 0,5 2 1 MIC
11 Ampicillin, AMP = 2 2 8 1 MIC
11 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
11 Chloramphenicol, CHL = 4 2 8 1 MIC
11 Ciprofloxacin, CIP = 0.016 0,004 0,016 1 MIC
11 Gentamicin, GEN = 0.5 0,25 1 1 MIC
11 Nalidixic acid, NAL <= 2 1 4 1 MIC
11 Streptomycin, STR = 4 4 16 1 MIC
11 Sulfisoxazole, FIS <= 8 8 32 1 MIC
11 Tetracycline, TET = 1 0,5 2 1 MIC
11 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
12 Ampicillin, AMP = 4 2 8 1 MIC
12 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
12 Ceftazidime, CAZ = 0.5 0,06 0,5 1 MIC
12 Chloramphenicol, CHL = 4 2 8 1 MIC
12 Ciprofloxacin, CIP = 0.03 0,004 0,016 0 MIC
12 Gentamicin, GEN = 1 0,25 1 1 MIC
12 Nalidixic acid, NAL = 2 1 4 1 MIC
12 Streptomycin, STR = 8 4 16 1 MIC
12 Tetracycline, TET <= 1 0,5 2 1 MIC
12 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
13 Ampicillin, AMP = 4 2 8 1 MIC
13 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
13 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
13 Chloramphenicol, CHL = 4 2 8 1 MIC
13 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
13 Gentamicin, GEN = 0.5 0,25 1 1 MIC
13 Nalidixic acid, NAL <= 4 1 4 1 MIC
13 Streptomycin, STR = 8 4 16 1 MIC
13 Sulfisoxazole, FIS = 32 8 32 1 MIC
13 Tetracycline, TET <= 1 0,5 2 1 MIC
13 Trimethoprim, TMP = 1 0,5 2 1 MIC
15 Cefotaxime, CTX = 35 29 35 1 DD
15 Cefoxitin, FOX = 27 23 29 1 DD
15 Ceftazidime, CAZ = 32 25 32 1 DD
15 Ceftiofur, XNL = 28 26 31 1 DD
15 Chloramphenicol, CHL = 27 21 27 1 DD
15 Gentamicin, GEN = 26 19 26 1 DD
15 Nalidixic acid, NAL = 24 22 28 1 DD
15 Streptomycin, STR = 20 12 20 1 DD
15 Tetracycline, TET = 25 18 25 1 DD
15 Trimethoprim, TMP = 24 21 28 1 DD
16 Ampicillin, AMP = 4 2 8 1 MIC
16 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
16 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
16 Chloramphenicol, CHL = 8 2 8 1 MIC
16 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
16 Gentamicin, GEN = 1 0,25 1 1 MIC
16 Nalidixic acid, NAL = 2 1 4 1 MIC
16 Streptomycin, STR = 8 4 16 1 MIC
16 Sulfisoxazole, FIS = 32 8 32 1 MIC
16 Tetracycline, TET <= 1 0,5 2 1 MIC
16 Trimethoprim, TMP = 2 0,5 2 1 MIC
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17 Ampicillin, AMP = 4 2 8 1 MIC
17 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
17 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
17 Chloramphenicol, CHL = 4 2 8 1 MIC
17 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
17 Gentamicin, GEN = 0.5 0,25 1 1 MIC
17 Nalidixic acid, NAL <= 4 1 4 1 MIC
17 Streptomycin, STR = 4 4 16 1 MIC
17 Sulfisoxazole, FIS = 16 8 32 1 MIC
17 Tetracycline, TET <= 1 0,5 2 1 MIC
17 Trimethoprim, TMP = 1 0,5 2 1 MIC
18 Ampicillin, AMP = 19 16 22 1 DD
18 Cefotaxime, CTX = 32 29 35 1 DD
18 Cefoxitin, FOX = 27 23 29 1 DD
18 Ceftazidime, CAZ = 29 25 32 1 DD
18 Chloramphenicol, CHL = 25 21 27 1 DD
18 Ciprofloxacin, CIP = 35 30 40 1 DD
18 Gentamicin, GEN = 22 19 26 1 DD
18 Nalidixic acid, NAL = 24 22 28 1 DD
18 Streptomycin, STR = 15 12 20 1 DD
18 Sulfisoxazole, FIS = 21 15 23 1 DD
18 Tetracycline, TET = 23 18 25 1 DD
19 Ampicillin, AMP = 2 2 8 1 MIC
19 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
19 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
19 Chloramphenicol, CHL = 8 2 8 1 MIC
19 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
19 Gentamicin, GEN = 1 0,25 1 1 MIC
19 Nalidixic acid, NAL = 4 1 4 1 MIC
19 Streptomycin, STR = 16 4 16 1 MIC
19 Sulfisoxazole, FIS = 32 8 32 1 MIC
19 Tetracycline, TET = 1 0,5 2 1 MIC
19 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
20 Ampicillin, AMP = 4 2 8 1 MIC
20 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
20 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
20 Chloramphenicol, CHL = 8 2 8 1 MIC
20 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
20 Gentamicin, GEN = 0.5 0,25 1 1 MIC
20 Nalidixic acid, NAL <= 4 1 4 1 MIC
20 Streptomycin, STR = 8 4 16 1 MIC
20 Sulfisoxazole, FIS = 32 8 32 1 MIC
20 Tetracycline, TET = 2 0,5 2 1 MIC
20 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
21 Ampicillin, AMP = 4 2 8 1 MIC
21 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
21 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
21 Chloramphenicol, CHL = 4 2 8 1 MIC
21 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
21 Gentamicin, GEN = 0.5 0,25 1 1 MIC
21 Nalidixic acid, NAL = 4 1 4 1 MIC
21 Sulfisoxazole, FIS = 16 8 32 1 MIC
21 Tetracycline, TET = 2 0,5 2 1 MIC
21 Trimethoprim, TMP = 1 0,5 2 1 MIC
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22 Ampicillin, AMP = 4 2 8 1 MIC
22 Cefotaxime, CTX < 0.06 0,03 0,125 1 MIC
22 Ceftazidime, CAZ < 0.25 0,06 0,5 1 MIC
22 Chloramphenicol, CHL = 4 2 8 1 MIC
22 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
22 Gentamicin, GEN = 0.5 0,25 1 1 MIC
22 Nalidixic acid, NAL < 4 1 4 1 MIC
22 Streptomycin, STR = 8 4 16 1 MIC
22 Sulfisoxazole, FIS = 32 8 32 1 MIC
22 Tetracycline, TET < 1 0,5 2 1 MIC
22 Trimethoprim, TMP = 1 0,5 2 1 MIC
23 Ampicillin, AMP = 4 2 8 1 MIC
23 Cefotaxime, CTX < 0.06 0,03 0,125 1 MIC
23 Cefoxitin, FOX < 4 2 8 1 MIC
23 Ceftazidime, CAZ < 0.25 0,06 0,5 1 MIC
23 Chloramphenicol, CHL = 4 2 8 1 MIC
23 Ciprofloxacin, CIP < 0.008 0,004 0,016 1 MIC
23 Gentamicin, GEN = 0.5 0,25 1 1 MIC
23 Nalidixic acid, NAL < 4 1 4 1 MIC
23 Streptomycin, STR = 4 4 16 1 MIC
23 Sulfisoxazole, FIS = 32 8 32 1 MIC
23 Tetracycline, TET < 1 0,5 2 1 MIC
23 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
25 Ampicillin, AMP = 4 2 8 1 MIC
25 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
25 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
25 Chloramphenicol, CHL = 4 2 8 1 MIC
25 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
25 Gentamicin, GEN = 0.5 0,25 1 1 MIC
25 Nalidixic acid, NAL <= 4 1 4 1 MIC
25 Streptomycin, STR = 8 4 16 1 MIC
25 Sulfisoxazole, FIS <= 8 8 32 1 MIC
25 Tetracycline, TET <= 1 0,5 2 1 MIC
25 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
26 Ampicillin, AMP = 4 2 8 1 MIC
26 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
26 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
26 Chloramphenicol, CHL = 4 2 8 1 MIC
26 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
26 Gentamicin, GEN = 1 0,25 1 1 MIC
26 Nalidixic acid, NAL <= 4 1 4 1 MIC
26 Streptomycin, STR = 8 4 16 1 MIC
26 Tetracycline, TET <= 1 0,5 2 1 MIC
26 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
29 Ampicillin, AMP = 4 2 8 1 MIC
29 Cefotaxime, CTX < 0.06 0,03 0,125 1 MIC
29 Ceftazidime, CAZ = 0.06 0,06 0,5 1 MIC
29 Ceftiofur, XNL = 27 26 31 1 DD
29 Chloramphenicol, CHL = 4 2 8 1 MIC
29 Ciprofloxacin, CIP = 0.016 0,004 0,016 1 MIC
29 Gentamicin, GEN = 0.5 0,25 1 1 MIC
29 Nalidixic acid, NAL < 2 1 4 1 MIC
29 Streptomycin, STR = 4 4 16 1 MIC
29 Tetracycline, TET = 2 0,5 2 1 MIC
29 Trimethoprim, TMP = 1 0,5 2 1 MIC
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30 Ampicillin, AMP = 2 2 8 1 MIC
30 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
30 Cefoxitin, FOX <= 4 2 8 1 MIC
30 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
30 Chloramphenicol, CHL = 4 2 8 1 MIC
30 Ciprofloxacin, CIP <= 0.008 0,004 0,016 1 MIC
30 Gentamicin, GEN = 0.5 0,25 1 1 MIC
30 Imipenem, IMI <= 0.5 0,06 0,25 1 MIC
30 Nalidixic acid, NAL <= 4 1 4 1 MIC
30 Streptomycin, STR = 4 4 16 1 MIC
30 Sulfisoxazole, FIS = 16 8 32 1 MIC
30 Tetracycline, TET <= 1 0,5 2 1 MIC
30 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
32 Ampicillin, AMP = 4 2 8 1 MIC
32 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
32 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
32 Chloramphenicol, CHL = 4 2 8 1 MIC
32 Ciprofloxacin, CIP <= 0.008 0,004 0,016 1 MIC
32 Gentamicin, GEN = 0.5 0,25 1 1 MIC
32 Nalidixic acid, NAL <= 4 1 4 1 MIC
32 Streptomycin, STR = 8 4 16 1 MIC
32 Sulfisoxazole, FIS = 16 8 32 1 MIC
32 Tetracycline, TET <= 1 0,5 2 1 MIC
32 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
33 Ampicillin, AMP = 4 2 8 1 MIC
33 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
33 Cefoxitin, FOX = 4 2 8 1 MIC
33 Ceftazidime, CAZ = 0.5 0,06 0,5 1 MIC
33 Chloramphenicol, CHL = 4 2 8 1 MIC
33 Ciprofloxacin, CIP = 0.03 0,004 0,016 0 MIC
33 Gentamicin, GEN = 0.5 0,25 1 1 MIC
33 Nalidixic acid, NAL = 4 1 4 1 MIC
33 Streptomycin, STR = 8 4 16 1 MIC
33 Sulfisoxazole, FIS = 16 8 32 1 MIC
33 Tetracycline, TET = 2 0,5 2 1 MIC
33 Trimethoprim, TMP = 1 0,5 2 1 MIC
34 Ampicillin, AMP = 2 2 8 1 MIC
34 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
34 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
34 Chloramphenicol, CHL = 4 2 8 1 MIC
34 Ciprofloxacin, CIP <= 0.008 0,004 0,016 1 MIC
34 Gentamicin, GEN = 0.5 0,25 1 1 MIC
34 Nalidixic acid, NAL <= 4 1 4 1 MIC
34 Streptomycin, STR = 4 4 16 1 MIC
34 Sulfisoxazole, FIS = 64 8 32 0 MIC
34 Tetracycline, TET <= 1 0,5 2 1 MIC
34 Trimethoprim, TMP = 1 0,5 2 1 MIC
36 Ampicillin, AMP = 2 2 8 1 MIC
36 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
36 Chloramphenicol, CHL = 4 2 8 1 MIC
36 Ciprofloxacin, CIP = 0.03 0,004 0,016 0 MIC
36 Gentamicin, GEN = 1 0,25 1 1 MIC
36 Nalidixic acid, NAL <= 2 1 4 1 MIC
36 Streptomycin, STR = 8 4 16 1 MIC
36 Tetracycline, TET = 1 0,5 2 1 MIC
36 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
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37 Ampicillin, AMP = 4 2 8 1 AGA
37 Cefotaxime, CTX <= 0.06 0,03 0,125 1 AGA
37 Chloramphenicol, CHL = 4 2 8 1 AGA
37 Ciprofloxacin, CIP <= 0.008 0,004 0,016 1 AGA
37 Gentamicin, GEN = 1 0,25 1 1 AGA
37 Nalidixic acid, NAL <= 2 1 4 1 AGA
37 Streptomycin, STR = 4 4 16 1 AGA
37 Tetracycline, TET = 1 0,5 2 1 AGA
37 Trimethoprim, TMP = 0.5 0,5 2 1 AGA
38 Ampicillin, AMP = 16.3 16 22 1 DD
38 Cefotaxime, CTX = 33.7 29 35 1 DD
38 Cefoxitin, FOX = 26.3 23 29 1 DD
38 Ceftazidime, CAZ = 29.5 25 32 1 DD
38 Chloramphenicol, CHL = 23.6 21 27 1 DD
38 Ciprofloxacin, CIP = 38.1 30 40 1 DD
38 Gentamicin, GEN = 24.0 19 26 1 DD
38 Imipenem, IMI = 29.2 26 32 1 DD
38 Nalidixic acid, NAL = 22.0 22 28 1 DD
38 Streptomycin, STR = 14.9 12 20 1 DD
38 Tetracycline, TET = 22.6 18 25 1 DD
38 Trimethoprim, TMP = 21.0 21 28 1 DD
39 Ampicillin, AMP = 4 2 8 1 MIC
39 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
39 Chloramphenicol, CHL = 4 2 8 1 MIC
39 Ciprofloxacin, CIP = 0.03 0,004 0,016 0 MIC
39 Gentamicin, GEN = 1 0,25 1 1 MIC
39 Nalidixic acid, NAL <= 2 1 4 1 MIC
39 Streptomycin, STR = 8 4 16 1 MIC
39 Sulfisoxazole, FIS = 32 8 32 1 MIC
39 Tetracycline, TET = 1 0,5 2 1 MIC
39 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
40 Ampicillin, AMP = 22 16 22 1 DD
40 Cefotaxime, CTX = 32 29 35 1 DD
40 Cefoxitin, FOX = 24 23 29 1 DD
40 Ceftazidime, CAZ = 30 25 32 1 DD
40 Ceftiofur, XNL = 26 26 31 1 DD
40 Chloramphenicol, CHL = 24 21 27 1 DD
40 Ciprofloxacin, CIP = 31 30 40 1 DD
40 Gentamicin, GEN = 23 19 26 1 DD
40 Imipenem, IMI = 29 26 32 1 DD
40 Nalidixic acid, NAL = 26 22 28 1 DD
40 Streptomycin, STR = 17 12 20 1 DD
40 Sulfisoxazole, FIS = 22 15 23 1 DD
40 Tetracycline, TET = 23 18 25 1 DD
40 Trimethoprim, TMP = 27 21 28 1 DD
41 Ampicillin, AMP = 4 2 8 1 MIC
41 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
41 Cefoxitin, FOX = 4 2 8 1 MIC
41 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
41 Ceftiofur, XNL = 0.5 0,25 1 1 MIC
41 Chloramphenicol, CHL = 8 2 8 1 MIC
41 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
41 Gentamicin, GEN = 0.5 0,25 1 1 MIC
41 Nalidixic acid, NAL = 2 1 4 1 MIC
41 Streptomycin, STR = 8 4 16 1 MIC
41 Tetracycline, TET <= 1 0,5 2 1 MIC
41 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
42 Ampicillin, AMP = 8 2 8 1 MIC
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42 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
42 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
42 Chloramphenicol, CHL = 8 2 8 1 MIC
42 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
42 Gentamicin, GEN = 0.5 0,25 1 1 MIC
42 Nalidixic acid, NAL <= 4 1 4 1 MIC
42 Streptomycin, STR = 4 4 16 1 MIC
42 Sulfisoxazole, FIS = 32 8 32 1 MIC
42 Tetracycline, TET = 2 0,5 2 1 MIC
42 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
44 Ampicillin, AMP <= 8 2 8 1 AGA
44 Cefotaxime, CTX <= 1 0,03 0,125 1 AGA
44 Cefoxitin, FOX = 3 2 8 1 AGA
44 Chloramphenicol, CHL <= 8 2 8 1 AGA
44 Ciprofloxacin, CIP = 0.006 0,004 0,016 1 AGA
44 Gentamicin, GEN <= 4 0,25 1 1 AGA
44 Imipenem, IMI = 0.125 0,06 0,25 1 AGA
44 Nalidixic acid, NAL <= 16 1 4 1 AGA
44 Streptomycin, STR <= 16 4 16 1 AGA
44 Sulfisoxazole, FIS <= 64 8 32 1 AGA
44 Tetracycline, TET <= 8 0,5 2 1 AGA
44 Trimethoprim, TMP <= 2 0,5 2 1 AGA
56 Ampicillin, AMP = 22 16 22 1 DD
56 Cefotaxime, CTX = 33 29 35 1 DD
56 Ceftazidime, CAZ = 30 25 32 1 DD
56 Ceftiofur, XNL = 28 26 31 1 DD
56 Chloramphenicol, CHL = 25 21 27 1 DD
56 Ciprofloxacin, CIP = 35 30 40 1 DD
56 Gentamicin, GEN = 23 19 26 1 DD
56 Nalidixic acid, NAL = 27 22 28 1 DD
56 Streptomycin, STR = 17 12 20 1 DD
56 Sulfisoxazole, FIS = 23 15 23 1 DD
56 Tetracycline, TET = 25 18 25 1 DD
56 Trimethoprim, TMP = 25 21 28 1 DD
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Test results from the reference strain C. jejuni ATCC 33560
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
1 Chloramphenicol, CHL = 8 1 8 1 MIC X
1 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
1 Erythromycin, ERY = 2 0,5 2 1 MIC X
1 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
1 Nalidixic acid, NAL = 8 4 16 1 MIC X
1 Tetracycline, TET = 4 0,25 2 0 MIC X
2 Chloramphenicol, CHL = 4 1 8 1 MIC X
2 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
2 Erythromycin, ERY = 1 0,5 2 1 MIC X
2 Gentamicin, GEN = 0.25 0,5 2 0 MIC X
2 Nalidixic acid, NAL = 8 4 16 1 MIC X
2 Tetracycline, TET = 2 0,25 2 1 MIC X
4 Chloramphenicol, CHL = 4 1 8 1 MIC X
4 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
4 Erythromycin, ERY = 1 0,5 2 1 MIC X
4 Nalidixic acid, NAL = 8 4 16 1 MIC X
4 Tetracycline, TET = 0.5 0,25 2 1 MIC X
6 Chloramphenicol, CHL = 2 1 4 1 MIC X
6 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
6 Erythromycin, ERY = 1 0,25 2 1 MIC X
6 Gentamicin, GEN = 0.5 0,25 2 1 MIC X
6 Nalidixic acid, NAL = 8 4 16 1 MIC X
6 Tetracycline, TET = 0.5 0,25 1 1 MIC X
9 Chloramphenicol, CHL = 4 1 8 1 MIC X
9 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
9 Erythromycin, ERY = 1 0,5 2 1 MIC X
9 Gentamicin, GEN = 1 0,5 2 1 MIC X
9 Nalidixic acid, NAL = 8 4 16 1 MIC X
9 Tetracycline, TET = 0.5 0,25 2 1 MIC X
11 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
11 Erythromycin, ERY = 1 0,5 2 1 MIC X
11 Gentamicin, GEN = 1 0,5 2 1 MIC X
11 Nalidixic acid, NAL = 8 4 16 1 MIC X
11 Tetracycline, TET = 1 0,25 2 1 MIC X
12 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
12 Erythromycin, ERY <= 0.5 0,5 2 1 MIC X
12 Gentamicin, GEN = 1 0,5 2 1 MIC X
12 Nalidixic acid, NAL = 16 4 16 1 MIC X
12 Tetracycline, TET = 1 0,25 2 1 MIC X
14 Chloramphenicol, CHL <= 2 1 4 1 MIC X
14 Ciprofloxacin, CIP = 0.125 0,03 0,125 1 MIC X
14 Erythromycin, ERY = 1 0,25 2 1 MIC X
14 Gentamicin, GEN = 1 0,25 2 1 MIC X
14 Nalidixic acid, NAL = 8 4 16 1 MIC X
14 Tetracycline, TET = 1 0,25 1 1 MIC X
17 Chloramphenicol, CHL <= 2 1 8 1 MIC X
17 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
17 Erythromycin, ERY = 2 0,5 2 1 MIC X
17 Gentamicin, GEN = 1 0,5 2 1 MIC X
17 Nalidixic acid, NAL = 8 4 16 1 MIC X
17 Tetracycline, TET = 0.5 0,25 2 1 MIC X
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19 Chloramphenicol, CHL = 4 1 4 1 MIC X
19 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
19 Erythromycin, ERY = 0.5 0,25 2 1 MIC X
19 Gentamicin, GEN = 1 0,25 2 1 MIC X
19 Nalidixic acid, NAL = 8 4 16 1 MIC X
19 Tetracycline, TET = 2 0,25 1 0 MIC X
20 Chloramphenicol, CHL = 4 1 8 1 MIC X
20 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
20 Erythromycin, ERY = 1 0,5 2 1 MIC X
20 Gentamicin, GEN = 1 0,5 2 1 MIC X
20 Nalidixic acid, NAL = 8 4 16 1 MIC X
20 Tetracycline, TET = 2 0,25 2 1 MIC X
22 Chloramphenicol, CHL < 2 1 4 1 MIC X
22 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
22 Erythromycin, ERY = 1 0,25 2 1 MIC X
22 Gentamicin, GEN = 1 0,25 2 1 MIC X
22 Nalidixic acid, NAL = 8 4 16 1 MIC X
22 Tetracycline, TET = 1 0,25 1 1 MIC X
23 Chloramphenicol, CHL < 2 1 4 1 MIC X
23 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
23 Erythromycin, ERY < 0.5 0,25 2 1 MIC X
23 Gentamicin, GEN = 1 0,25 2 1 MIC X
23 Nalidixic acid, NAL = 8 4 16 1 MIC X
23 Tetracycline, TET = 1 0,25 1 1 MIC X
25 Chloramphenicol, CHL = 4 1 8 1 MIC X
25 Ciprofloxacin, CIP <= 0.12 0,06 0,25 1 MIC X
25 Erythromycin, ERY = 2 0,5 2 1 MIC X
25 Gentamicin, GEN <= 0.25 0,5 2 0 MIC X
25 Nalidixic acid, NAL = 8 4 16 1 MIC X
25 Tetracycline, TET = 2 0,25 2 1 MIC X
26 Chloramphenicol, CHL = 4 1 8 1 MIC X
26 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
26 Erythromycin, ERY = 1 0,5 2 1 MIC X
26 Gentamicin, GEN = 1 0,5 2 1 MIC X
26 Nalidixic acid, NAL = 8 4 16 1 MIC X
26 Tetracycline, TET = 2 0,25 2 1 MIC X
29 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
29 Erythromycin, ERY = 0.50 0,5 2 1 MIC X
29 Gentamicin, GEN = 16 0,5 2 0 MIC X
29 Nalidixic acid, NAL = 1 4 16 0 MIC X
29 Tetracycline, TET = 0.5 0,25 2 1 MIC X
30 Chloramphenicol, CHL = 4 1 8 1 MIC X
30 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
30 Erythromycin, ERY = 1 0,5 2 1 MIC X
30 Gentamicin, GEN = 1 0,5 2 1 MIC X
30 Nalidixic acid, NAL = 8 4 16 1 MIC X
30 Tetracycline, TET = 2 0,25 2 1 MIC X
32 Chloramphenicol, CHL <= 2 1 4 1 MIC X
32 Ciprofloxacin, CIP = 0.125 0,03 0,125 1 MIC X
32 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
32 Gentamicin, GEN = 0.5 0,25 2 1 MIC X
32 Nalidixic acid, NAL = 4 4 16 1 MIC X
32 Tetracycline, TET = 1 0,25 1 1 MIC X
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33 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
33 Erythromycin, ERY = 2 0,5 2 1 MIC X
33 Gentamicin, GEN = 1 0,5 2 1 MIC X
33 Nalidixic acid, NAL = 16 4 16 1 MIC X
33 Tetracycline, TET = 2 0,25 2 1 MIC X
34 Chloramphenicol, CHL = 8 1 8 1 MIC X
34 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
34 Erythromycin, ERY = 2 0,5 2 1 MIC X
34 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
34 Nalidixic acid, NAL = 8 4 16 1 MIC X
34 Tetracycline, TET = 2 0,25 2 1 MIC X
36 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
36 Erythromycin, ERY = 1 0,5 2 1 MIC X
36 Gentamicin, GEN = 1 0,5 2 1 MIC X
36 Nalidixic acid, NAL = 8 4 16 1 MIC X
36 Tetracycline, TET = 1 0,25 2 1 MIC X
37 Chloramphenicol, CHL = 4 0 256 0 AGA X
37 Ciprofloxacin, CIP = 0.125 0,12 1 1 AGA X
37 Erythromycin, ERY = 2 1 8 1 AGA X
37 Gentamicin, GEN = 2 0,5 2 1 AGA X
37 Nalidixic acid, NAL = 8 0 256 0 AGA X
37 Tetracycline, TET = 1 0 256 0 AGA X
39 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
39 Erythromycin, ERY = 2 0,5 2 1 MIC X
39 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
39 Nalidixic acid, NAL = 8 4 16 1 MIC X
39 Tetracycline, TET = 2 0,25 2 1 MIC X
41 Chloramphenicol, CHL <= 2 1 4 1 MIC X
41 Ciprofloxacin, CIP <= 0.06 0,03 0,125 1 MIC X
41 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
41 Gentamicin, GEN = 0.5 0,25 2 1 MIC X
41 Nalidixic acid, NAL = 4 4 16 1 MIC X
41 Tetracycline, TET = 0.5 0,25 1 1 MIC X
42 Chloramphenicol, CHL = 8 MIC
42 Ciprofloxacin, CIP = 0.25 MIC
42 Erythromycin, ERY = 4 MIC
42 Gentamicin, GEN <= 0.12 MIC
42 Nalidixic acid, NAL = 16 MIC
42 Tetracycline, TET = 4 MIC
44 Chloramphenicol, CHL < 8 0 256 0 AGA X
44 Ciprofloxacin, CIP < 1 0,12 1 1 AGA X
44 Erythromycin, ERY < 4 1 8 1 AGA X
44 Gentamicin, GEN < 1 0,5 2 1 AGA X
44 Nalidixic acid, NAL < 16 0 256 0 AGA X
44 Tetracycline, TET < 2 0 256 0 AGA X
37°C 24 h 
37°C 24 h 
37°C 24 h 
37°C 24 h 
37°C 24 h 
37°C 24 h 
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QC ranges for reference strains
Antimicrobial MIC E-test
Ampicillin, AMP 2-8 2-8
Cefotaxime, CTX 0.03-0.12 0.03-0.12
Cefoxitin, FOX 2-8 None
Ceftazidime, CAZ 0.06-0.5 0.06-0.5
Ceftiofur, XNL 0.25-1 None
Chloramphenicol, CHL 2-8 None
Ciprofloxacin, CIP 0.004-0.016 None
Gentamicin, GEN 0.25-1 None
Imipenem, IMI 0.06-0.25 0.06-0.25
Nalidixic acid, NAL 1-4 1-4
Streptomycin, STR 4-16 2-8
Sulfisoxazole, FIS 8-32 32-128
Tetracycline, TET 0.5-2 0.5-2
Trimethoprim, TMP 0.5-2 0.5-2
E-test ranges are according to AB-Biodisk
Antimicrobial Microbroth                
(36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution     
(36-37°C/48h)
Agar dilution     
(42°C/24h)
Chloramphenicol, CHL 1-8 1-4 None None
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
19-26 (10µg)
26-32 (10µg)
18-25 (30µg)
Ranges are according to CLSI (M31-A3) 
Campylobacter jejuni ATCC 33560
E. coli ATCC 25922
DD (disc content)
16-22 (10µg)
29-35 (30µg)
23-29 (30µg)
25-32 (30µg)
26-31 (30µg)
21-27 (30µg)
21-28 (5µg)
MIC ranges and disc diffusion ranges are according to CLSI M100 S21 with the following exceptions: 
The MIC range for streptomycin is according to Sensititre and the range for ceftiofur is according to 
M31-A3. Additionally, the range for ciprofloxacin is extended to include 0.016 as well.
22-28 (30µg)
12-20 (10µg)
15-23 (250/300µg)
30-40 (5µg)
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Test range for MIC (µg/mL)-Salmonella
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
Ampicillin, AMP Chloramphenicol, CHL Nalidixic acid, NAL Tetracycline, TET
1 MIC 1-32 1 MIC 2-64 1 MIC 4-64 1 MIC 2-32
2 MIC 0.5-32 2 MIC 2-64 2 MIC 4-64 2 MIC 1-64
4 MIC 0.5-32 4 MIC 2-64 4 MIC 4-64 4 MIC 1-64
6 MIC 0.5-32 6 MIC 2-64 6 MIC 4-64 6 MIC 1-64
9 MIC 0.5-32 9 MIC 2-64 9 MIC 4-64 9 MIC 1-64
11 MIC 0.5-64 11 MIC 2-256 11 MIC 2-256 11 MIC 0.5-64
12 MIC 1-128 12 MIC 2-64 12 MIC 1-128 12 MIC 1-128
13 MIC 0.5-32 13 MIC 2-64 13 MIC 8-64 13 MIC 1-64
16 MIC 1-128 16 MIC 2-256 16 MIC 1-128 16 MIC 1-128
17 MIC 0.5-32 17 MIC 2-64 17 MIC 4-64 17 MIC 1-64
22 MIC 0.5-32 22 MIC 2-64 22 MIC 4-64 22 MIC 1-64
22 MIC 0.5-32 22 MIC 2-64 22 MIC 4-64 22 MIC 1-64
23 MIC 0.5-32 23 MIC 2-64 23 MIC 4-64 23 MIC 1-64
25 MIC 0.5-32 25 MIC 2-64 25 MIC 4-64 25 MIC 1-64
26 MIC 0.5-32 26 MIC 2-64 26 MIC 4-64 26 MIC 1-64
29 MIC >4 29 MIC >16 29 MIC >16 29 MIC >8
30 MIC 0.5-32 30 MIC 2-64 30 MIC 4-64 30 MIC 1-64
32 MIC 0,5-32 32 MIC 2-64 32 MIC 4-64 32 MIC 1-64
33 MIC 0.5-64 33 MIC 2-256 33 MIC 2-256 33 MIC 0.5-64
36 MIC 0.5-64 36 MIC 2-256 36 MIC 2-256 36 MIC 0.5-64
37 AGA 0.5-64 37 AGA 2-256 37 AGA 2-512 37 AGA 0.5-64
39 MIC 0.5-64 39 MIC 2-256 39 MIC 2-256 39 MIC 0.5-64
41 MIC 0.5-32 41 MIC 2-64 41 MIC 4-64 41 MIC 1-64
42 MIC 0.5-32 42 MIC 2-64 42 MIC 4-64 42 MIC 1-64
44 AGA 8 and 128 44 AGA 8 44 AGA 16 44 AGA 8 and 128
Cefotaxime, CTX Ciprofloxacin, CIP Streptomycin, STR Trimethoprim, TMP
1 MIC 0.125-4 1 MIC 0.015-4 1 MIC 8-128 1 MIC 1-32
2 MIC 0.06-4 2 MIC 0.008-8 2 MIC 2-128 2 MIC 0.5-32
4 MIC 0.06-4 4 MIC 0.008-8 4 MIC 2-128 4 MIC 0.5-32
6 MIC 0.06-4 6 MIC 0.008-8 6 MIC 2-128 6 MIC 0.5-32
9 MIC 0.06-4 9 MIC 0.008-8 9 MIC 2-128 9 MIC 0.5-32
11 MIC 0.06-8 11 MIC 0.008-1 11 MIC 2-256 11 MIC 0.25-32
12 MIC 0.016-2 12 MIC 0.008-1 12 MIC 2-256 12 MIC 0.12-16
13 MIC 0.06-4 13 MIC 0.008-8 13 MIC 2-128 13 MIC 0.5-32
16 MIC 0.015-2 16 MIC 0.008-4 16 MIC 2-256 16 MIC 0.12-16
17 MIC 0.06-4 17 MIC 0.008-8 17 MIC 2-128 17 MIC 0.5-32
22 MIC 0.06-4 22 MIC 0.008-8 22 MIC 2-128 22 MIC 0.5-32
22 MIC 0.06-4 22 MIC 0.008-8 22 MIC 2-128 22 MIC 0.5-32
23 MIC 0.06-4 23 MIC 0.008-8 23 MIC 2-128 23 MIC 0.5-32
25 MIC 0.06-4 25 MIC 0.008-8 25 MIC 2-128 25 MIC 0.5-32
26 MIC 0.06-4 26 MIC 0.008-8 26 MIC 2-128 26 MIC 0.5-32
29 MIC >0.5 29 MIC >0.06 29 MIC >32 29 MIC >2
30 MIC 0.06-4 30 MIC 0.008-8 30 MIC 2-128 30 MIC 0.5-32
32 MIC 0,06-4 32 MIC 0.008-8 32 MIC 2-128 32 MIC 0,5-32
33 MIC 0.06-8 33 MIC 0.008-8 33 MIC 2-256 33 MIC 0.25-32
36 MIC 0.06-8 36 MIC 0.008-1 36 MIC 2-256 36 MIC 0.25-32
37 AGA 0.06-8 37 AGA 0.008-8 37 AGA 2-512 37 AGA 0.25-32
39 MIC 0.06-8 39 MIC 0.008-1 39 MIC 2-256 39 MIC 0.25-32
41 MIC 0.06-4 41 MIC 0.008-8 41 MIC 2-128 41 MIC 0.5-32
42 MIC 0.06-4 42 MIC 0.008-8 42 MIC 2-128 42 MIC 0.5-32
44 AGA 1 44 AGA 0.125 and 1 44 AGA 16 and 128 44 AGA 2
Ceftazidime, CAZ Gentamicin, GEN Sulfamethoxazole, SMX
2 MIC 0.25-16 1 MIC 0.5-16 1 MIC 64-1024      Antimicrobials recommended 
4 MIC 0.25-16 2 MIC 0.25-32 2 MIC 8-1024      by EFSA are marked in grey
6 MIC 0.25-16 4 MIC 0.25-32 4 MIC 8-1024
9 MIC 0.25-16 6 MIC 0.25-32 6 MIC 8-1024      Participants' ranges covering 
12 MIC 0.25-16 9 MIC 0.25-32 9 MIC 8-1024      the EFSA range are 
13 MIC 0.25-16 11 MIC 0.25-32 11 MIC 8-1024      marked in grey
16 MIC 0.06-8 12 MIC 0.12-16 12 MIC 16-2048
17 MIC 0.25-16 13 MIC 0.25-32 13 MIC 8-1024      MIC: Microbroth dilution
22 MIC 0.25-16 16 MIC 0.12-16 16 MIC 8-1024      AGA: Agar dilution
22 MIC 0.25-16 17 MIC 0.25-32 17 MIC 8-1024
23 MIC 0.25-16 22 MIC 0.25-32 22 MIC 8-1024
25 MIC 0.25-16 22 MIC 0.25-32 22 MIC 8-1024
26 MIC 0.25-16 23 MIC 0.25-32 23 MIC 8-1024
29 MIC >2 25 MIC 0.25-32 25 MIC 8-1024
30 MIC 0.25-16 26 MIC 0.25-32 26 MIC 8-1024
32 MIC 0,25-16 29 MIC >2 29 MIC >256
39 MIC N/A 30 MIC 0.25-32 30 MIC 8-1024
41 MIC 0.25-16 32 MIC 0.25-32 32 MIC 8-1024
42 MIC 0.25-16 33 MIC 0.25-32 33 MIC 8-1024
Ceftiofur, XNL 36 MIC 0.25-32 36 MIC 8-1024
1 MIC 0.5-8 37 AGA 0.25-32 37 AGA 8-1024
12 MIC 0.12-16 39 MIC 0.25-32 39 MIC 8-1024
23 MIC 0,12-8 41 MIC 0.25-32 41 MIC 8-1024
29 MIC >2 42 MIC 0.25-32 42 MIC 8-1024
39 MIC N/A 44 AGA 4 44 AGA 64
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Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
1 MIC 2-32 1 MIC 0.125-16 1 MIC 1-16
2 MIC 2-64 2 MIC 0.12-16 2 MIC 0.5 -32
4 MIC 2-32 4 MIC 0.12-16 4 MIC 1-16
6 MIC 2-32 6 MIC 0.12-16 6 MIC 1-16
9 MIC 2-32 9 MIC 0,12-16 9 MIC 1-16
14 MIC 2-32 11 MIC 0.12-16 11 MIC 0.5-64
17 MIC 2-32 12 MIC 0.12-16 12 MIC 0.5-64
19 MIC 2-32 14 MIC 0.125-16 14 MIC 1-16
20 MIC 2-32 17 MIC 0.12-16 17 MIC 1-16
21 MIC 1-32 19 MIC 0.12-16 19 MIC 1-16
22 MIC 2-32 20 MIC 0.12-16 20 MIC 1-16
23 MIC 2-32 21 MIC 0.12-128 21 MIC 0.12-128
25 MIC 2-128 22 MIC 0.12-16 22 MIC 1-16
26 MIC 2-32 23 MIC 0.12-16 23 MIC 1-16
30 MIC 2-32 25 MIC 0.25-32 25 MIC 1-128
32 MIC 2-32 26 MIC 0.12-16 26 MIC 1-16
34 MIC 1 to 32 29 MIC 0.12-16 29 MIC 0.5-64
37 AGA 2-256 30 MIC 0.12-16 30 MIC 1-16
39 MIC N/A 32 MIC 0.125-16 32 MIC 1-16
41 MIC 2-32 33 MIC 0.12-16 33 MIC 0.5-64
42 MIC 2-32 34 MIC 0.125 to 32 34 MIC 0.25 to 64
44 AGA 8 36 MIC 0,12-16 36 MIC 0,5-64
37 AGA 0.125-16 37 AGA 0.5-32
1 MIC 0.06-4 39 MIC 0.12-16 39 MIC 0.5-64
2 MIC 0.06-32 41 MIC 0.12-16 41 MIC 1-16
4 MIC 0.06-4 42 MIC 0.12-16 42 MIC 1-16
6 MIC 0.06-4 44 AGA 4 44 AGA not tested
9 MIC 0,06-4
11 MIC 0.06-8 1 MIC 2-64 1 MIC 0.25-16
12 MIC 0.06-8 2 MIC 2-256 2 MIC 0.12-64
14 MIC 0.06-4 4 MIC 2-64 4 MIC 0.25-16
17 MIC 0.06-4 6 MIC 2-64 6 MIC 0.25-16
19 MIC 0.06-4 9 MIC 2-64 9 MIC 0,25-16
20 MIC 0.06-4 11 MIC 1-64 11 MIC 0.12-16
21 MIC 0.06-128 12 MIC 1-64 12 MIC 0.12-16
22 MIC 0.06-4 14 MIC 2-64 14 MIC 0.25-16
23 MIC 0.06-4 17 MIC 2-64 17 MIC 0.25-16
25 MIC 0.12-16 19 MIC 2-64 19 MIC 0.25-16
26 MIC 0.06-4 20 MIC 2-64 20 MIC 0.25-16
29 MIC 0.06-8 21 MIC 0.12-128 21 MIC 0.12-128
30 MIC 0.06-4 22 MIC 2-64 22 MIC 0.25-16
32 MIC 0.06-4 23 MIC 2-64 23 MIC 0.25-16
33 MIC 0.06-8 25 MIC 1-128 25 MIC 0.5-64
34 MIC 0.032 to 32 26 MIC 2-64 26 MIC 0.25-16
36 MIC 0.06-8 29 MIC 1-64 29 MIC 0.12-16
37 AGA 0.06-8 30 MIC 2-64 30 MIC 0.25-16
39 MIC 0.06-8 32 MIC 2-64 32 MIC 0.25-16
41 MIC 0.06-4 33 MIC 1-64 33 MIC 0.12-16
42 MIC 0.06-4 34 MIC 0.5 to 64 34 MIC 0.125 to 256
44 AGA 1 36 MIC 1-64 36 MIC 0,12-16
37 AGA 2-256 37 AGA 0.125-16
1 MIC 0.5-32 39 MIC 1-64 39 MIC 0.12-16
2 MIC 0.25-128 41 MIC 2-64 41 MIC 0.25-16
4 MIC 0.5-32 42 MIC 2-64 42 MIC 0.25-16
6 MIC 0.5-32 44 AGA 16 44 AGA 8 & 128
9 MIC 0,5-32
11 MIC 0.5-64
12 MIC 0.5-64
14 MIC 0.5-32
17 MIC 0.5-32      Antimicrobials recommended by EFSA are marked in grey
19 MIC 0.5-32      Participants' ranges covering the EFSA range are marked in grey
20 MIC 0.5-32
21 MIC 0.12-128      MIC: Microbroth dilution
22 MIC 0.5-32      AGA: Agar dilution
23 MIC 0.5-32
25 MIC 0.5-64
26 MIC 0.5-32
29 MIC 0.5-64
30 MIC 0.5-32
32 MIC 0.5-32
33 MIC 0.5-64
34 MIC 0.125 to 128
36 MIC 0,5-64
37 AGA 0.5-64
39 MIC 0.5-64
41 MIC 0.5-32
42 MIC 0.5-32
44 AGA 4
Erythromycin, ERY
Tetracycline,TETNalidixic acid, NAL
Ciprofloxacin, CIP
Chloramphenicol, CHL Gentamicin, GEN Streptomycin, STR
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Salmonella - expected and obtained interpretation
Antimicrobial Strain Expected % R % S No. 
correct
No. 
incorrect
EURL S-6.1 R 100 0 33 0
EURL S-6.2 R 100 0 33 0
EURL S-6.3 R 100 0 33 0
EURL S-6.4 R 100 0 33 0
EURL S-6.5 S 0 100 33 0
EURL S-6.6 S 0 100 33 0
EURL S-6.7 S 0 100 33 0
EURL S-6.8 R 100 0 33 0
EURL S-6.1 R 100 0 34 0
EURL S-6.2 S 0 100 34 0
EURL S-6.3 R 97 3 33 1
EURL S-6.4 R 97 3 33 1
EURL S-6.5 S 0 100 34 0
EURL S-6.6 S 0 100 34 0
EURL S-6.7 S 0 100 34 0
EURL S-6.8 R 97 3 33 1
EURL S-6.1 R 96 4 27 1
EURL S-6.2 S 0 100 28 0
EURL S-6.3 R 97 3 28 1
EURL S-6.4 S 11 89 25 3
EURL S-6.5 S 0 100 28 0
EURL S-6.6 S 0 100 28 0
EURL S-6.7 S 0 100 28 0
EURL S-6.8 R 100 0 28 0
EURL S-6.1 R 100 0 8 0
EURL S-6.2 S 0 100 8 0
EURL S-6.3 R 100 0 8 0
EURL S-6.4 R 88 13 7 1
EURL S-6.5 S 0 100 8 0
EURL S-6.6 S 0 100 8 0
EURL S-6.7 S 0 100 8 0
EURL S-6.8 R 100 0 8 0
EURL S-6.1 S 0 100 34 0
EURL S-6.2 R 100 0 34 0
EURL S-6.3 R 100 0 33 0
EURL S-6.4 S 0 100 33 0
EURL S-6.5 S 0 100 34 0
EURL S-6.6 S 0 100 33 0
EURL S-6.7 S 0 100 34 0
EURL S-6.8 R 100 0 34 0
EURL S-6.1 S 0 100 33 0
EURL S-6.2 R 94 6 31 2
EURL S-6.3 R 82 18 27 6
EURL S-6.4 R 97 3 32 1
EURL S-6.5 S 0 100 33 0
EURL S-6.6 S 0 100 33 0
EURL S-6.7 R 82 18 27 6
EURL S-6.8 S 0 100 33 0
Ampicillin, AMP
Ciprofloxacin, CIP
Chloramphenicol, CHL
Ceftiofur, XNL
Ceftazidime, CAZ
Cefotaxime, CTX
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EURL S-6.1 S 0 100 34 0
EURL S-6.2 S 0 100 34 0
EURL S-6.3 R 97 3 33 1
EURL S-6.4 S 3 97 33 1
EURL S-6.5 S 0 100 34 0
EURL S-6.6 S 0 100 34 0
EURL S-6.7 S 3 97 33 1
EURL S-6.8 S 0 100 34 0
EURL S-6.1 S 0 100 33 0
EURL S-6.2 R 100 0 33 0
EURL S-6.3 S 12 88 29 4
EURL S-6.4 R 100 0 33 0
EURL S-6.5 S 0 100 33 0
EURL S-6.6 S 0 100 33 0
EURL S-6.7 S 6 94 31 2
EURL S-6.8 S 0 100 33 0
EURL S-6.1 S 0 100 34 0
EURL S-6.2* R 55 45 18 15
EURL S-6.3 R 100 0 34 0
EURL S-6.4 S 9 91 30 3
EURL S-6.5 S 0 100 34 0
EURL S-6.6* R 48 52 16 17
EURL S-6.7 S 9 91 31 3
EURL S-6.8 R 100 0 34 0
EURL S-6.1 S 0 100 33 0
EURL S-6.2 R 100 0 33 0
EURL S-6.3 R 100 0 33 0
EURL S-6.4 S 3 97 32 1
EURL S-6.5 S 3 97 32 1
EURL S-6.6 R 94 6 31 2
EURL S-6.7 S 25 75 24 8
EURL S-6.8 R 100 0 33 0
EURL S-6.1 S 0 100 34 0
EURL S-6.2 R 97 3 33 1
EURL S-6.3 R 100 0 34 0
EURL S-6.4 R 97 3 33 1
EURL S-6.5 S 0 100 34 0
EURL S-6.6 R 100 0 34 0
EURL S-6.7 S 0 100 34 0
EURL S-6.8 R 100 0 34 0
EURL S-6.1 S 0 100 33 0
EURL S-6.2 R 100 0 33 0
EURL S-6.3 R 100 0 33 0
EURL S-6.4 S 3 97 32 1
EURL S-6.5 S 0 100 33 0
EURL S-6.6 R 100 0 32 0
EURL S-6.7 S 0 100 32 0
EURL S-6.8 S 0 100 32 0
*Strain/antimicrobial-combination excluded from the evaluation
Nalidixic acid, NAL
Trimethoprim, TMP
Tetracycline, TET
Sulphonamides, SMX
Streptomycin, STR
Gentamicin, GEN
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Campylobacter  - expected and obtained interpretation
 
Antimicrobial Strain Expected % R % S No. correct
No. 
incorrect
EURL C-6.1 S 0 100 20 0
EURL C-6.2 S 0 100 19 0
EURL C-6.3 S 0 100 20 0
EURL C-6.4 S 0 100 20 0
EURL C-6.5 S 0 100 20 0
EURL C-6.6 S 0 100 20 0
EURL C-6.7 S 0 100 20 0
EURL C-6.8 S 0 100 20 0
EURL C-6.1 S 4 96 24 1
EURL C-6.2 S 4 96 23 1
EURL C-6.3 R 100 0 25 0
EURL C-6.4 R 100 0 25 0
EURL C-6.5 R 100 0 26 0
EURL C-6.6 R 100 0 26 0
EURL C-6.7 S 0 100 26 0
EURL C-6.8 S 0 100 26 0
EURL C-6.1 S 0 100 25 0
EURL C-6.2 S 4 96 23 1
EURL C-6.3 S 0 100 25 0
EURL C-6.4 S 0 100 25 0
EURL C-6.5 R 92 8 24 2
EURL C-6.6 S 4 96 25 1
EURL C-6.7 R 100 0 26 0
EURL C-6.8 R 100 0 26 0
EURL C-6.1 S 4 96 23 1
EURL C-6.2 S 0 100 24 0
EURL C-6.3 S 0 100 25 0
EURL C-6.4 S 0 100 25 0
EURL C-6.5 S 0 100 26 0
EURL C-6.6 S 4 96 25 1
EURL C-6.7 S 0 100 26 0
EURL C-6.8 S 0 100 26 0
EURL C-6.1 S 4 96 24 1
EURL C-6.2 S 4 96 23 1
EURL C-6.3 S 16 84 21 4
EURL C-6.4 R 96 4 23 1
EURL C-6.5 R 96 4 25 1
EURL C-6.6 R 96 4 25 1
EURL C-6.7 S 0 100 26 0
EURL C-6.8 S 0 100 26 0
EURL C-6.1 S 4 96 24 1
EURL C-6.2 S 13 88 21 3
EURL C-6.3 S 8 92 23 2
EURL C-6.4 S 4 96 24 1
EURL C-6.5 S 4 96 25 1
EURL C-6.6 S 8 92 24 2
EURL C-6.7 S 15 85 22 4
EURL C-6.8 R 100 0 26 0
EURL C-6.1 S 0 100 25 0
EURL C-6.2 R 100 0 24 0
EURL C-6.3 S 0 100 25 0
EURL C-6.4 R 96 4 24 1
EURL C-6.5 R 96 4 25 1
EURL C-6.6 S 4 96 25 1
EURL C-6.7 S 0 100 26 0
EURL C-6.8 S 0 100 26 0
Chloramphenicol, CHL
Tetracycline, TET
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
Ciprofloxacin, CIP
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Deviations - Salmonella
Lab no. Strain Antimicrobial Obtained interpretation
Obtained 
value
Expected 
interpretation
Expected 
MIC
Method 
used
4 EURL S-6.3 Nalidixic acid, NAL R 8 S = 8 MIC
4 EURL S-6.4 Ceftazidime, CAZ R 0.5 S = 1 MIC
4 EURL S-6.7 Gentamicin, GEN R 2 S = 0.5 MIC
4 EURL S-6.7 Nalidixic acid, NAL R 8 S = 8 MIC
4 EURL S-6.7 Streptomycin, STR R 16 S = 16 MIC
4 EURL S-6.7 Sulfamethoxazole, SMX R 1024 S = 64 MIC
4 EURL S-6.8 Confirmed ESBL Yes No MIC
12 EURL S-6.6 Sulfamethoxazole, SMX S 256 R > 1024 MIC
13 EURL S-6.4 Streptomycin, STR R 8 S = 16 MIC
15 EURL S-6.3 Nalidixic acid, NAL R 15 S = 8 DD
15 EURL S-6.4 Cefotaxime, CTX S 20 R > 4 DD
15 EURL S-6.7 Nalidixic acid, NAL R 15 S = 8 DD
18 EURL S-6.3 Ciprofloxacin, CIP S 32 R = 0.25 DD
18 EURL S-6.7 Ciprofloxacin, CIP S 31 R = 0.25 DD
20 EURL S-6.7 Streptomycin, STR R 32 S = 16 MIC
21 EURL S-6.1 Confirmed ESBL No Yes MIC
21 EURL S-6.3 Nalidixic acid, NAL R 64 S = 8 MIC
21 EURL S-6.4 Ceftazidime, CAZ R 0.5 S = 1 MIC
21 EURL S-6.4 Sulfamethoxazole, SMX R 1024 S = 64 MIC
21 EURL S-6.4 Trimethoprim, TMP R >32 S <= 1 MIC
22 EURL S-6.7 Sulfamethoxazole, SMX R >1024 S = 64 MIC
22 EURL S-6.8 Confirmed ESBL Yes No MIC
23 EURL S-6.7 Sulfamethoxazole, SMX R 512 S = 64 MIC
26 EURL S-6.3 Cefotaxime, CTX S <=0.06 R > 4 MIC
26 EURL S-6.3 Ceftazidime, CAZ S <=0.25 R = 128 MIC
26 EURL S-6.3 Confirmed ESBL No Yes MIC
26 EURL S-6.3 Gentamicin, GEN S 1 R > 16 MIC
26 EURL S-6.3 Nalidixic acid, NAL R 64 S = 8 MIC
26 EURL S-6.4 Streptomycin, STR R 32 S = 16 MIC
29 EURL S-6.4 Ceftiofur, XNL S 22mm R > 8 MIC
29 EURL S-6.7 Sulfamethoxazole, SMX R 512 S = 64 MIC
30 EURL S-6.4 Ceftazidime, CAZ R 1 S = 1 MIC
33 EURL S-6.4 Gentamicin, GEN R 4 S = 1 MIC
33 EURL S-6.7 Confirmed AmpC Yes No MIC
38 EURL S-6.1 Ceftazidime, CAZ S 17.5 mm R = 8 DD
38 EURL S-6.3 Ciprofloxacin, CIP S 31.8 mm R = 0.25 DD
38 EURL S-6.4 Streptomycin, STR R 9.4 mm S = 16 DD
38 EURL S-6.7 Ciprofloxacin, CIP S 33.4 mm R = 0.25 DD
38 EURL S-6.7 Streptomycin, STR R 10.9 mm S = 16 DD
38 EURL S-6.8 Confirmed AmpC No Yes DD
39 EURL S-6.5 Sulfamethoxazole, SMX R 1024 S = 64 MIC
39 EURL S-6.7 Sulfamethoxazole, SMX R 1024 S = 64 MIC
39 EURL S-6.8 Confirmed AmpC No Yes MIC
40 EURL S-6.2 Ciprofloxacin, CIP S 32 R = 0.25 DD
40 EURL S-6.2 Tetracycline, TET S 13 R > 32 DD
40 EURL S-6.3 Ciprofloxacin, CIP S 31 R = 0.25 DD
40 EURL S-6.4 Tetracycline, TET S 13 R > 32 DD
40 EURL S-6.6 Sulfamethoxazole, SMX S 27 R > 1024 DD
40 EURL S-6.7 Ciprofloxacin, CIP S 33 R = 0.25 DD
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41 EURL S-6.7 Sulfamethoxazole, SMX R 512 S = 64 MIC
41 EURL S-6.8 Confirmed AmpC No Yes MIC
42 EURL S-6.7 Sulfamethoxazole, SMX R 512 S = 64 MIC
44 EURL S-6.3 Ciprofloxacin, CIP S <=0.125 R = 0.25 AGA
44 EURL S-6.7 Ciprofloxacin, CIP S <=0.125 R = 0.25 AGA
54 EURL S-6.1 Confirmed ESBL No Yes DD
54 EURL S-6.2 Ciprofloxacin, CIP S 17 R = 0.25 DD
54 EURL S-6.3 Ciprofloxacin, CIP S 19 R = 0.25 DD
54 EURL S-6.3 Confirmed ESBL No Yes DD
54 EURL S-6.4 Ciprofloxacin, CIP S 17 R = 0.5 DD
54 EURL S-6.4 Confirmed ESBL No Yes DD
54 EURL S-6.7 Ciprofloxacin, CIP S 20 R = 0.25 DD
54 EURL S-6.8 Cefotaxime, CTX S 16 R > 4 DD
54 EURL S-6.8 Confirmed AmpC No Yes DD
56 EURL S-6.3 Ciprofloxacin, CIP S 27 R = 0.25 DD
56 EURL S-6.4 Confirmed ESBL No Yes DD
56 EURL S-6.7 Ciprofloxacin, CIP S 27 R = 0.25 DD
56 EURL S-6.7 Sulfamethoxazole, SMX R 6 S = 64 DD
AGA Agar dilution
DD Disk diffusion
ET E-test
MIC Microbroth dilution
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Deviations - Campylobacter
Lab no. Strain Antimicrobial Obtained 
interpretation
Obtained 
value
Expected 
interpretation
Expected MIC Method 
used
4 EURL C-6.1 Ciprofloxacin, CIP R 4 S = 0.12 MIC
4 EURL C-6.1 Gentamicin, GEN R 1 S = 0.25 MIC
4 EURL C-6.1 Nalidixic acid, NAL R 64 S = 4 MIC
4 EURL C-6.2 Ciprofloxacin, CIP R 4 S = 0.12 MIC
4 EURL C-6.2 Erythromycin, ERY R 8 S = 1 MIC
4 EURL C-6.2 Nalidixic acid, NAL R 32 S = 4 MIC
4 EURL C-6.2 Streptomycin, STR R 2 S <= 1 MIC
4 EURL C-6.3 Nalidixic acid, NAL R 32 S <= 2 MIC
4 EURL C-6.3 Streptomycin, STR R 2 S <= 1 MIC
4 EURL C-6.4 Streptomycin, STR R 2 S <= 1 MIC
4 EURL C-6.4 Tetracycline, TET S 0.25 R = 32 MIC
4 EURL C-6.6 Streptomycin, STR R 4 S = 4 MIC
4 EURL C-6.7 Streptomycin, STR R 8 S = 2 MIC
6 EURL C-6.6 Nalidixic acid, NAL S =32 R > 64 MIC
17 EURL C-6.4 Nalidixic acid, NAL S 16 R > 64 MIC
17 EURL C-6.5 Nalidixic acid, NAL S 32 R > 64 MIC
19 EURL C-6.1 Streptomycin, STR R 4 S <= 1 MIC
19 EURL C-6.2 Streptomycin, STR R 8 S <= 1 MIC
19 EURL C-6.3 Nalidixic acid, NAL R 64 S <= 2 MIC
19 EURL C-6.3 Streptomycin, STR R 4 S <= 1 MIC
19 EURL C-6.5 Erythromycin, ERY S 32 R > 64 MIC
19 EURL C-6.6 Gentamicin, GEN R 4 S = 0.5 MIC
19 EURL C-6.6 Streptomycin, STR R 16 S = 4 MIC
19 EURL C-6.7 Streptomycin, STR R 8 S = 2 MIC
22 EURL C-6.2 Streptomycin, STR R 4 S <= 1 MIC
22 EURL C-6.3 Nalidixic acid, NAL R 64 S <= 2 MIC
22 EURL C-6.7 Streptomycin, STR R 8 S = 2 MIC
29 EURL C-6.5 Streptomycin, STR R 8 S <= 1 MIC
33 EURL C-6.7 Streptomycin, STR R 8 S = 2 MIC
34 EURL C-6.3 Nalidixic acid, NAL R 32 S <= 2 MIC
39 EURL C-6.5 Erythromycin, ERY S 4 R > 64 MIC
39 EURL C-6.5 Tetracycline, TET S 0.5 R > 64 MIC
39 EURL C-6.6 Erythromycin, ERY R >64 S = 1 MIC
39 EURL C-6.6 Tetracycline, TET R >16 S = 0.25 MIC
AGA Agar dilution
MIC Microbroth dilution
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Optional genotypic characterisation
Lab no. Strain Not 
detected 
Primer used 5’→3’ Primer used 3’→5’ PCR-
method
Reference
I EURL GEN-3.1 blaZ In-house
I EURL GEN-3.1 mecA In-house
I EURL GEN-3.1 vga(A) In-house
I EURL GEN-3.1 tet(K) In-house
I EURL GEN-3.1 tet(M) In-house
I EURL GEN-3.1 aacA-aphD X 5'-TAATCCAAGAGCAATAAGGGC-3' 5'-GCCACACTATCATAACCACTA-3' In-house
I EURL GEN-3.1 cat X 5'-GGATATGAAATTTATCCCTC-3' 5'-CAATCATCTACCCTATGAAT-3' In-house
I EURL GEN-3.1 tet(O) X In-house
I EURL GEN-3.2 CMY -2 In-house
I EURL GEN-3.2 floR
I EURL GEN-3.2 aadA
I EURL GEN-3.2 strB
I EURL GEN-3.2 sul1 In-house
I EURL GEN-3.2 sul2
I EURL GEN-3.2 tetA
I EURL GEN-3.2 aac(3)-II X
I EURL GEN-3.2 aac(3)-IV X
I EURL GEN-3.2 ant(2'')-I X
III EURL GEN-3.1 blaI
III EURL GEN-3.1 blaR
III EURL GEN-3.1 blaZ
III EURL GEN-3.1 mecA
III EURL GEN-3.1 tet(K)
III EURL GEN-3.1 tet(M)
III EURL GEN-3.1 vga(A)
III EURL GEN-3.1 aacA-aphD X
III EURL GEN-3.1 aadD X
III EURL GEN-3.1 aphA3 X
III EURL GEN-3.1 cat X
III EURL GEN-3.1 vanA X
III EURL GEN-3.1 vanB X
III EURL GEN-3.1 vanZ X
III EURL GEN-3.1 lnu(A) X Published Van Hoek et al, 2011
III EURL GEN-3.1 erm(A) X
III EURL GEN-3.1 erm(B) X
III EURL GEN-3.1 erm(C) X
III EURL GEN-3.1 mef(A) X
III EURL GEN-3.1 msr(A) X
III EURL GEN-3.1 qacA X
III EURL GEN-3.1 far1 X
III EURL GEN-3.1 vat(A) X
III EURL GEN-3.1 vat(B) X
III EURL GEN-3.1 vgB(A) X
III EURL GEN-3.1 sat X
III EURL GEN-3.1 dfrA X
Gene tested
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III EURL GEN-3.2 CMY -2 Published Zhao et al., 2001
III EURL GEN-3.2 floR Published Ng et al, 1999, AAC
III EURL GEN-3.2 aadA Published Sandvang et al, 1997
III EURL GEN-3.2 strA Published Madsen et al, 2000
III EURL GEN-3.2 strB Published Madsen et al, 2000
III EURL GEN-3.2 sul1 Published Sandvang et al, 1997
III EURL GEN-3.2 sul2 Published Chu et al, 2001
III EURL GEN-3.2 tetA Published Ng et al., 1999, MCP
III EURL GEN-3.2 CTX X Published Carattoli et al. 2008
III EURL GEN-3.2 OXA X Published Guerra et al., 2000
III EURL GEN-3.2 SHV X Published Weill et al. 2004
III EURL GEN-3.2 TEM X Published Guerra et al. 2001; Olesen et al. 2004
III EURL GEN-3.2 catA1 X Published Guerra et al. 2001
III EURL GEN-3.2 cmlA X Published Guerra et al. 2001
III EURL GEN-3.2 aac(3)-II X Published Beutlich et al., 2011
III EURL GEN-3.2 aac(3)-IV X Published Guerra et al. 2001
III EURL GEN-3.2 aac(3)-Ie X
III EURL GEN-3.2 ant(2'')-I X Published Frana et al, 2001
III EURL GEN-3.2 aph(3')-I X Published Frana et al., 2001
III EURL GEN-3.2 aph(3')-II X Published Frana et al., 2001
III EURL GEN-3.2 aph(3')-III X Published Gibreel et al.
III EURL GEN-3.2 gyrA-83 X Published Malorny et al. 2003
III EURL GEN-3.2 gyrA-87 X Published Malorny et al. 2003
III EURL GEN-3.2 parC-57 X Published Malorny et al. 2003
III EURL GEN-3.2 parC-78 X Published Malorny et al. 2003
III EURL GEN-3.2 parC-80 X Published Malorny et al. 2003
III EURL GEN-3.2 parC-84 X Published Malorny et al. 2003
III EURL GEN-3.2 qnrA X Published Wang et al., 2003
III EURL GEN-3.2 qnrB X Published Jacoby et al., 2006
III EURL GEN-3.2 qnrC X Published Wang et al., 2009
III EURL GEN-3.2 qnrD X Published Cavaco et al, 2009
III EURL GEN-3.2 qnrS X Published Gay et al., 2006
III EURL GEN-3.2 sul3 X Published Perreten & Boerlin, 2003 
III EURL GEN-3.2 tetB X Published Ng et al., 1999, MCP
III EURL GEN-3.2 tetC X Published Ng et al., 1999, MCP
III EURL GEN-3.2 tetD X Published Ng et al., 1999, MCP
III EURL GEN-3.2 tetE X Published Ng et al., 1999, MCP
III EURL GEN-3.2 tetG X Published Ng et al., 1999, MCP
IV EURL GEN-3.1 blaI
IV EURL GEN-3.1 blaR
IV EURL GEN-3.1 blaZ
IV EURL GEN-3.1 mecA
IV EURL GEN-3.1 tet(M)
IV EURL GEN-3.2 CMY -2
IV EURL GEN-3.2 floR
IV EURL GEN-3.2 aadA
IV EURL GEN-3.2 strA
IV EURL GEN-3.2 strB
IV EURL GEN-3.2 sul1
IV EURL GEN-3.2 sul2
IV EURL GEN-3.2 tetA
VI EURL GEN-3.2 qnrA X GGATGCCAGTTTCGAGGA TGCCAGGCACAGATCTTG Published PCR qnr genes CRL-AR 1th Ed. January 2009
VI EURL GEN-3.2 qnrB X GGMATHGAAATTCGCCACTG TTTGCYGYYCGCCAGTCGAA Published PCR qnr genes CRL-AR 1th Ed. January 2009
VI EURL GEN-3.2 qnrC X GGGTTGTACATTTATTGAATC TCCACTTTACGAGGTTCT Published Antimicrob.AgentsChemother, May2099, 1892-1897
VI EURL GEN-3.2 qnrD X CGAGATCAATTTACGGGGAATA AACAAGCTGAAGCGCCTG Published PCR qnr genes CRL-AR 1th Ed. January 2009
VI EURL GEN-3.2 qnrS X TCGACGTGCTAACTTGCG GATCTAAACCGTCGAGTTCGG Published PCR qnr genes CRL-AR 1th Ed. January 2009
VI EURL GEN-3.2 qepA X
VI EURL GEN-3.2 aac(6")Ib-cr X
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VII EURL GEN-3.1 mecA Published Batchelor et al AAC (2005) 49:1319-1322.
VII EURL GEN-3.2 Salmonella  Amp-C  Cit-group
VIII EURL GEN-3.2 CMY AMR-ve 0.5m
VIII EURL GEN-3.2 floR AMR-ve 0.5m
VIII EURL GEN-3.2 aadA AMR-ve 0.5m
VIII EURL GEN-3.2 strA AMR-ve 0.5m
VIII EURL GEN-3.2 strB AMR-ve 0.5m
VIII EURL GEN-3.2 sul1 AMR-ve 0.5m
VIII EURL GEN-3.2 sul2 AMR-ve 0.5m
VIII EURL GEN-3.2 tetA AMR-ve 0.5m
VIII EURL GEN-3.2 CTX X AMR-ve 0.5m
VIII EURL GEN-3.2 OXA X AMR-ve 0.5m
VIII EURL GEN-3.2 SHV X AMR-ve 0.5m
VIII EURL GEN-3.2 TEM X AMR-ve 0.5m
VIII EURL GEN-3.2 catA1 X AMR-ve 0.5m
VIII EURL GEN-3.2 cmlA X AMR-ve 0.5m
VIII EURL GEN-3.2 aac(3)-II X AMR-ve 0.5m
VIII EURL GEN-3.2 aac(3)-IV X AMR-ve 0.5m
VIII EURL GEN-3.2 ant(2'')-I X AMR-ve 0.5m
VIII EURL GEN-3.2 qnrA X AMR-ve 0.5m
VIII EURL GEN-3.2 qnrB X AMR-ve 0.5m
VIII EURL GEN-3.2 qnrS X AMR-ve 0.5m
VIII EURL GEN-3.2 sul3 X AMR-ve 0.5m
VIII EURL GEN-3.2 tetB X AMR-ve 0.5m
VIII EURL GEN-3.2 tetC X AMR-ve 0.5m
VIII EURL GEN-3.2 tetD X AMR-ve 0.5m
VIII EURL GEN-3.2 tetE X AMR-ve 0.5m
VIII EURL GEN-3.2 tetG X AMR-ve 0.5m
Legend: 
Fields shaded grey indicate that the gene was expected
Genes in bold were detected but not expected 
Field with an unexpected result are framed
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